<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id><journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id><journal-id journal-id-type="publisher-id">JAH3</journal-id><journal-id journal-id-type="hwp">ahaoa</journal-id><journal-title-group><journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title></journal-title-group><issn pub-type="epub">2047-9980</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28887315</article-id><article-id pub-id-type="pmc">5634294</article-id><article-id pub-id-type="doi">10.1161/JAHA.117.006478</article-id><article-id pub-id-type="publisher-id">JAH32448</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group subj-group-type="heading"><subject>Coronary Heart Disease</subject></subj-group></subj-group></article-categories><title-group><article-title>Inorganic Nitrate in Angina Study: A Randomized Double&#x02010;Blind Placebo&#x02010;Controlled Trial</article-title><alt-title alt-title-type="left-running-head">Schwarz et&#x000a0;al</alt-title></title-group><contrib-group><contrib id="jah32448-cr-0001" contrib-type="author"><name><surname>Schwarz</surname><given-names>Konstantin</given-names></name><degrees>MD, MRCP, PhD</degrees><xref ref-type="aff" rid="jah32448-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jah32448-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah32448-cr-0002" contrib-type="author"><name><surname>Singh</surname><given-names>Satnam</given-names></name><degrees>MBBS, MRCP</degrees><xref ref-type="aff" rid="jah32448-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32448-cr-0003" contrib-type="author"><name><surname>Parasuraman</surname><given-names>Satish K.</given-names></name><degrees>MBBS, MRCP</degrees><xref ref-type="aff" rid="jah32448-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jah32448-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jah32448-cr-0004" contrib-type="author"><name><surname>Rudd</surname><given-names>Amelia</given-names></name><degrees>RDCS</degrees><xref ref-type="aff" rid="jah32448-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32448-cr-0005" contrib-type="author"><name><surname>Shepstone</surname><given-names>Lee</given-names></name><degrees>BSc, MSc, PhD</degrees><xref ref-type="aff" rid="jah32448-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jah32448-cr-0006" contrib-type="author"><name><surname>Feelisch</surname><given-names>Martin</given-names></name><degrees>MSc, PhD</degrees><xref ref-type="aff" rid="jah32448-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="jah32448-cr-0007" contrib-type="author"><name><surname>Minnion</surname><given-names>Magdalena</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="jah32448-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="jah32448-cr-0008" contrib-type="author"><name><surname>Ahmad</surname><given-names>Shakil</given-names></name><degrees>BSc, PhD</degrees><xref ref-type="aff" rid="jah32448-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="jah32448-cr-0009" contrib-type="author"><name><surname>Madhani</surname><given-names>Melanie</given-names></name><degrees>BSc Hons, PhD</degrees><xref ref-type="aff" rid="jah32448-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="jah32448-cr-0010" contrib-type="author"><name><surname>Horowitz</surname><given-names>John</given-names></name><degrees>MBBS, BMedSci Hons, PhD, FRACP</degrees><xref ref-type="aff" rid="jah32448-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="jah32448-cr-0011" contrib-type="author"><name><surname>Dawson</surname><given-names>Dana K.</given-names></name><degrees>MD, FRCP, DPhil, FESC</degrees><xref ref-type="aff" rid="jah32448-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32448-cr-0012" contrib-type="author" corresp="yes"><name><surname>Frenneaux</surname><given-names>Michael P.</given-names></name><degrees>MBBS Hons, FRCP, MD, FRACP, FESC, FACC, FMedSci</degrees><address><email>M.Frenneaux@uea.ac.uk</email></address><xref ref-type="aff" rid="jah32448-aff-0003">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="jah32448-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">School of Medicine &#x00026; Dentistry</named-content>
<institution>University of Aberdeen</institution>
<named-content content-type="city">Aberdeen</named-content>
<country country="GB">UK</country>
</aff><aff id="jah32448-aff-0002">
<label><sup>2</sup></label>
<institution>Royal Wolverhampton Hospital</institution>
<named-content content-type="city">Wolverhampton</named-content>
<country country="GB">UK</country>
</aff><aff id="jah32448-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Norwich Medical School</named-content>
<institution>University of East Anglia</institution>
<named-content content-type="city">Norwich</named-content>
<country country="GB">UK</country>
</aff><aff id="jah32448-aff-0004">
<label><sup>4</sup></label>
<institution>University of Southampton</institution>
<named-content content-type="city">Southampton</named-content>
<country country="GB">UK</country>
</aff><aff id="jah32448-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Aston Medical Research Institute</named-content>
<institution>Aston University</institution>
<named-content content-type="city">Birmingham</named-content>
<country country="GB">UK</country>
</aff><aff id="jah32448-aff-0006">
<label><sup>6</sup></label>
<named-content content-type="organisation-division">Basil Hetzel Institute</named-content>
<institution>University of Adelaide</institution>
<named-content content-type="city">Adelaide</named-content>
<country country="AU">Australia</country>
</aff><aff id="jah32448-aff-0007">
<label><sup>7</sup></label>
<named-content content-type="organisation-division">Institute of Cardiovascular Sciences</named-content>
<institution>University of Birmingham</institution>
<named-content content-type="city">Birmingham</named-content>
<country country="GB">UK</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> Michael P. Frenneaux, MBBS (Hons), FRCP, MD, FRACP, FESC, FACC, FMedSci, Bob Champion Research and Education Building, James Watson Road, University of East Anglia, Norwich Research Park, Norwich, United Kingdom. E&#x02010;mail: <email>M.Frenneaux@uea.ac.uk</email></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2017</year></pub-date><volume>6</volume><issue>9</issue><issue-id pub-id-type="doi">10.1002/jah3.2017.6.issue-9</issue-id><elocation-id>e006478</elocation-id><history><date date-type="received"><day>11</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>22</day><month>6</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JAH3-6-e006478.pdf"/><abstract id="jah32448-abs-0001"><sec id="jah32448-sec-0001"><title>Background</title><p>In this double&#x02010;blind randomized placebo&#x02010;controlled crossover trial, we investigated whether oral sodium nitrate, when added to existing background medication, reduces exertional ischemia in patients with angina.</p></sec><sec id="jah32448-sec-0002"><title>Methods and Results</title><p>Seventy patients with stable angina, positive electrocardiogram treadmill test, and either angiographic or functional test evidence of significant ischemic heart disease were randomized to receive oral treatment with either placebo or sodium nitrate (600&#x000a0;mg; 7&#x000a0;mmol) for 7 to 10&#x000a0;days, followed by a 2&#x02010;week washout period before crossing over to the other treatment (n=34 placebo&#x02010;nitrate, n=36 nitrate&#x02010;placebo). At baseline and at the end of each treatment, patients underwent modified Bruce electrocardiogram treadmill test, modified Seattle Questionnaire, and subgroups were investigated with dobutamine stress, echocardiogram, and blood tests. The primary outcome was time to 1&#x000a0;mm <styled-content style="fixed-case">ST</styled-content> depression on electrocardiogram treadmill test. Compared with placebo, inorganic nitrate treatment tended to increase the primary outcome exercise time to 1&#x000a0;mm <styled-content style="fixed-case">ST</styled-content> segment depression (645.6 [603.1, 688.0] seconds versus 661.2 [6183, 704.0] seconds, <italic>P</italic>=0.10) and significantly increased total exercise time (744.4 [702.4, 786.4] seconds versus 760.9 [719.5, 802.2] seconds, <italic>P</italic>=0.04; mean [95% confidence interval]). Nitrate treatment robustly increased plasma nitrate (18.3 [15.2, 21.5] versus 297.6 [218.4, 376.8] &#x003bc;mol/L, <italic>P</italic>&#x0003c;0.0001) and almost doubled circulating nitrite concentrations (346 [285, 405] versus 552 [398, 706] nmol/L, <italic>P</italic>=0.003; placebo versus nitrate treatment). Other secondary outcomes were not significantly altered by the intervention. Patients on antacid medication appeared to benefit less from nitrate supplementation.</p></sec><sec id="jah32448-sec-0003"><title>Conclusions</title><p>Sodium nitrate treatment may confer a modest exercise capacity benefit in patients with chronic angina who are taking other background medication.</p></sec><sec id="jah32448-sec-0004"><title>Clinical Trial Registration</title><p>
<styled-content style="fixed-case">URL</styled-content>: <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/">https://www.clinicaltrials.gov/</ext-link>. Unique identifier: <styled-content style="fixed-case">NCT</styled-content>02078921. Eudra<styled-content style="fixed-case">CT</styled-content> number: 2012&#x02010;000196&#x02010;17.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jah32448-kwd-0001">angina</kwd><kwd id="jah32448-kwd-0002">exercise</kwd><kwd id="jah32448-kwd-0003">inorganic nitrate</kwd><kwd id="jah32448-kwd-0004">ischemia</kwd><kwd id="jah32448-kwd-0005">nitrite</kwd><kwd id="jah32448-kwd-0006">randomized trial</kwd></kwd-group><kwd-group kwd-group-type="subject-categories"><title>Subject Categories</title><kwd>Ischemia</kwd></kwd-group><funding-group><award-group><funding-source>Medical Research Council</funding-source><award-id>G1001536</award-id></award-group></funding-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="16"/><word-count count="7903"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jah32448</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.2.0 mode:remove_FC converted:26.09.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jah32448-cit-1001">(<source>J Am Heart Assoc</source>. <year>2017</year>;<volume>6</volume>:<elocation-id>e006478</elocation-id> DOI: <ext-link ext-link-type="doi" xlink:href="10.1161/JAHA.117.006478">10.1161/JAHA.117.006478</ext-link>.)<pub-id pub-id-type="pmid">28887315</pub-id></mixed-citation>
</p></notes></front><body><p>
<boxed-text position="anchor" content-type="box" id="jah32448-blkfxd-0001" orientation="portrait"><sec id="jah32448-sec-0006"><title>Clinical Perspective</title><sec id="jah32448-sec-0007"><title>What Is New?</title><p>
<list list-type="bullet" id="jah32448-list-0001"><list-item><p>In patients suffering from chronic angina, sodium nitrate treatment appears to have a modest anti&#x02010;ischemic effect when added to other background medication.</p></list-item><list-item><p>We report a trend toward improved myocardial ischemia and significantly increased exercise capacity.</p></list-item><list-item><p>Patients with stomach acid suppression appeared less likely to benefit, and mild nausea and vomiting were rarely reported.</p></list-item></list>
</p></sec><sec id="jah32448-sec-0008"><title>What Are the Clinical Implications?</title><p>
<list list-type="bullet" id="jah32448-list-0002"><list-item><p>Although there is currently not enough evidence to recommend routine sodium nitrate supplementation to patients with angina, increased dietary inorganic nitrate intake from sources such as green leafy vegetables is unlikely to cause any significant side effects, may improve exercise capacity, and can be recommended as a natural complement to other medication in patients with chronic angina.</p></list-item><list-item><p>The treatment period was relatively short, and a longer&#x02010;term supplementation trial will need to be established in future studies.</p></list-item></list>
</p></sec></sec></boxed-text>
</p><sec id="jah32448-sec-0009"><title>Introduction</title><p>Clinicians are increasingly encountering patients with diffuse coronary artery disease years after their revascularization, when repeated intervention is either impossible or of limited benefit. Approximately 30% of &#x0201c;completely revascularized&#x0201d; patients still continue to experience angina.<xref rid="jah32448-bib-0001" ref-type="ref">1</xref> Current antianginal drugs are very effective, but their use can be precluded because of side effects (especially bradycardia or hypotension).</p><p>Experimental evidence suggests that targeting the nitrate&#x02010;nitrite&#x02010;nitric oxide pathway may have therapeutic potential in patients with angina. Plasma nitrite is derived both from oxidation of endothelium&#x02010;derived nitric oxide and from dietary sources via bioconversion of nitrate involving an enterosalivary circulation, reduction by the oral microbial flora, and low stomach pH.<xref rid="jah32448-bib-0002" ref-type="ref">2</xref>
</p><p>The vasodilator effect of nitrite is potentiated by hypoxia<xref rid="jah32448-bib-0003" ref-type="ref">3</xref>, <xref rid="jah32448-bib-0004" ref-type="ref">4</xref>, <xref rid="jah32448-bib-0005" ref-type="ref">5</xref>, <xref rid="jah32448-bib-0006" ref-type="ref">6</xref> and, unlike organic nitrates (eg, glyceryl trinitrate [GTN], isosorbide 5&#x02010;mononitrate, and isosorbide dinitrate), not subject to development of tolerance.<xref rid="jah32448-bib-0007" ref-type="ref">7</xref>
</p><p>Nitrate has been reported to improve metabolic efficiency during exercise in human skeletal muscle, but it is unknown whether this also occurs in cardiac muscle.<xref rid="jah32448-bib-0008" ref-type="ref">8</xref>, <xref rid="jah32448-bib-0009" ref-type="ref">9</xref>, <xref rid="jah32448-bib-0010" ref-type="ref">10</xref>, <xref rid="jah32448-bib-0011" ref-type="ref">11</xref>, <xref rid="jah32448-bib-0012" ref-type="ref">12</xref> Under experimental conditions both nitrite and nitrate led to protection from ischemia&#x02010;reperfusion injury,<xref rid="jah32448-bib-0013" ref-type="ref">13</xref>, <xref rid="jah32448-bib-0014" ref-type="ref">14</xref>, <xref rid="jah32448-bib-0015" ref-type="ref">15</xref>, <xref rid="jah32448-bib-0016" ref-type="ref">16</xref>, <xref rid="jah32448-bib-0017" ref-type="ref">17</xref> blood pressure reduction,<xref rid="jah32448-bib-0018" ref-type="ref">18</xref>, <xref rid="jah32448-bib-0019" ref-type="ref">19</xref>, <xref rid="jah32448-bib-0020" ref-type="ref">20</xref>, <xref rid="jah32448-bib-0021" ref-type="ref">21</xref> reversal of pulmonary arterial hypertension,<xref rid="jah32448-bib-0005" ref-type="ref">5</xref>, <xref rid="jah32448-bib-0022" ref-type="ref">22</xref>, <xref rid="jah32448-bib-0023" ref-type="ref">23</xref> and induction of angiogenesis.<xref rid="jah32448-bib-0024" ref-type="ref">24</xref>, <xref rid="jah32448-bib-0025" ref-type="ref">25</xref>, <xref rid="jah32448-bib-0026" ref-type="ref">26</xref>
</p><p>In light of these preclinical experimental results we hypothesized that oral sodium nitrate supplementation will delay the onset of myocardial ischemia in patients suffering from chronic angina.</p></sec><sec id="jah32448-sec-0010"><title>Methods</title><sec id="jah32448-sec-0011"><title>Design</title><p>This randomized double&#x02010;blind, placebo&#x02010;controlled crossover trial (Figure&#x000a0;<xref rid="jah32448-fig-0001" ref-type="fig">1</xref>) was approved by the Scotland A Research Ethics Committee, subject to Medicines and Healthcare products Regulatory Agency regulation, and run in accordance with the Declaration of Helsinki. All patients signed an informed written consent.</p><fig fig-type="Figure" xml:lang="en" id="jah32448-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>CONSORT diagram. DSE indicates dobutamine stress echocardiogram; ETT, electrocardiogram treadmill test; LBBB, left bundle branch block; LVEF, left ventricle ejection fraction; STD, ST segment depression.</p></caption><graphic id="nlm-graphic-1" xlink:href="JAH3-6-e006478-g001"/></fig></sec><sec id="jah32448-sec-0012"><title>Patient Selection and Protocols</title><p>Patients aged &#x02265;18&#x000a0;years with exertional angina (&#x02265;2&#x000a0;months duration) were recruited.</p><p>Inclusion criteria comprised a positive electrocardiogram treadmill test (ETT) and either angiographic evidence of obstructive coronary artery disease or, if not available, a positive functional test (dobutamine stress echocardiogram [DSE] or myocardial perfusion scan). Exclusion criteria were inability to perform ETT, significant valvular disease, nonsinus rhythm, women of childbearing potential, G6PD (glucose&#x02010;6&#x02010;phosphate dehydrogenase) deficiency, LV ejection fraction &#x0003c;45% or New York Heart Association heart failure class III or IV, myocardial infarction or coronary revascularization within the past 2&#x000a0;months, resting ST segment depression &#x02265;1&#x000a0;mm, or left bundle branch block.</p><p>Patients were screened with modified Bruce&#x02010;protocol ETTs on separate days and enrolled only if they had replicable difference (&#x02264;15%) in time to 1&#x02010;mm ST segment depression between the first and the second screening.<xref rid="jah32448-bib-0027" ref-type="ref">27</xref>
</p><p>Patients continued regular medications including antianginal agents at a fixed dose with the exception of long&#x02010;acting organic nitrates, which were stopped at least 72&#x000a0;hours before enrollment. The latter served to avoid potential interaction between organic and inorganic nitrates, which partially act via similar downstream pathways and may confound the outcome. The use of short&#x02010;acting sublingual GTN was allowed. Some patients undergoing a concomitant DSE were asked to omit their &#x003b2;&#x02010;blocker for 48&#x000a0;hours before their visits (to facilitate their dobutamine response) at the discretion of the researcher, mainly depending on symptom severity, and the&#x000a0;elected strategy was used consistently throughout the screening and all subsequent visits. This approach was permissible due to the crossover design in which each patient served as his or her own control.</p></sec><sec id="jah32448-sec-0013"><title>Study Outcomes</title><p>The primary outcome was the time to a 1&#x02010;mm ST segment depression on ETT.</p><p>Secondary outcomes were time to chest pain onset, total exercise time, angina and GTN use frequency, modified Seattle Questionnaire, nitrate and nitrite plasma levels, angiogenic markers, and myocardial contractility assessment by peak systolic velocity measured by Doppler imaging (details described elsewhere).<xref rid="jah32448-bib-0028" ref-type="ref">28</xref>
</p></sec><sec id="jah32448-sec-0014"><title>Intervention and Randomization Process</title><p>The trial medication was manufactured and placed into packs containing 2 bottles labeled 1 and 2 at the Western Glasgow Infirmary Pharmacy. Each bottle contained 14 capsules with either 600&#x000a0;mg (7&#x000a0;mmol) of sodium nitrate or placebo (lactose monohydrate).</p><p>Researchers and patients were blinded to the randomization sequence in individual packs. Patients started treatment with bottle 1, 1 capsule a day for a period of 7 to 10&#x000a0;days, before undergoing a treadmill test and/or DSE and/or blood tests. After a 2&#x02010;week washout period the same procedure was repeated with bottle 2. Compliance with medication was assessed by patient via a checklist and by an investigator calculating the remaining capsules from return bottles.<xref rid="jah32448-bib-0028" ref-type="ref">28</xref> Patients were asked to follow a low&#x02010;nitrate and &#x02010;nitrite diet, limit caffeine intake, and avoid use of antibacterial mouthwash.<xref rid="jah32448-bib-0029" ref-type="ref">29</xref> The 600&#x02010;mg sodium nitrate dose was based on previous evidence that 300 mg to 600&#x000a0;mg of oral nitrate was effective in multiple studies assessing effects on blood pressure and exercise capacity in human volunteers.<xref rid="jah32448-bib-0010" ref-type="ref">10</xref>, <xref rid="jah32448-bib-0011" ref-type="ref">11</xref>, <xref rid="jah32448-bib-0020" ref-type="ref">20</xref>, <xref rid="jah32448-bib-0021" ref-type="ref">21</xref>, <xref rid="jah32448-bib-0030" ref-type="ref">30</xref>
</p></sec><sec id="jah32448-sec-0015"><title>Exercise Treadmill Test</title><p>Four ETTs, 2 screening and 1 following each treatment period, were performed at the same time of day, in an air&#x02010;conditioned room (21&#x000b0;C), &#x02248;2&#x000a0;hours following ingestion of the last study capsule, on a CASE Exercise Testing System (GE Healthcare, Chicago, IL). Automated blood pressure (BP) (Tango, SunTech Medical, Morrisville, NC) and 12&#x02010;lead ECGs were recorded in a standing position before exercise, at the end of each 3&#x02010;minute stage, at the time of first 1&#x02010;mm ST depression, at the time of first chest pain onset, at peak exercise, and every 3&#x000a0;minutes into recovery. In patients with minor resting ST depression (&#x0003c;1&#x000a0;mm), the time to 1&#x02010;mm ST change was defined as additional ST depression of 1&#x000a0;mm below the resting value.<xref rid="jah32448-bib-0031" ref-type="ref">31</xref> A 1&#x02010;mm ST depression was digitally detected and displayed by the CASE software at the J point (+80&#x000a0;milliseconds).<xref rid="jah32448-bib-0028" ref-type="ref">28</xref>
</p></sec><sec id="jah32448-sec-0016"><title>Dobutamine Stress Echocardiography</title><p>All patients were invited to participate in the DSE subgroup. Details of the full protocol are provided elsewhere.<xref rid="jah32448-bib-0028" ref-type="ref">28</xref> In brief, patients with inducible regional wall motion abnormalities and satisfactory echo windows who tolerated the baseline scan were enrolled. Exams were performed on a Vivid 9 machine (GE Healthcare) &#x02248;2&#x000a0;hours after completion of the treadmill test. The protocol involved acquisition at rest, baseline, and the following stages with incremental dobutamine dose: 10, 20, 30, and 40&#x000a0;&#x003bc;g/kg per minute. For the screening test we used left ventricle contrast (Sonovue, Bracco Imaging, Milan, Italy) in order to improve sensitivity of detection of inducible regional wall abnormalities.<xref rid="jah32448-bib-0032" ref-type="ref">32</xref> For on&#x02010;treatment tests, images were obtained without contrast using Doppler tissue velocity imaging in apical views and later analyzed using Echo PAC (version 1.113; GE Healthcare). Longitudinal basal segment peak systolic velocity was measured in 6 basal segments as previously described.<xref rid="jah32448-bib-0033" ref-type="ref">33</xref> The percentage increase in peak systolic velocity at peak dobutamine stage versus baseline was used for the final analysis. Differences in global and ischemic segment only (as defined on screening contrast test) were analyzed.<xref rid="jah32448-bib-0028" ref-type="ref">28</xref>
</p></sec><sec id="jah32448-sec-0017"><title>Blood Tests, Modified Seattle Questionnaire, GTN Use, and Angina Frequency</title><p>A subgroup of 20 patients underwent blood tests for nitrate and nitrite levels and angiogenic markers (soluble fms&#x02010;like tyrosine kinase receptor&#x02010;1, placental growth ractor, and vascular endothelial growth factor) levels. Samples were collected and analyzed as previously reported.<xref rid="jah32448-bib-0028" ref-type="ref">28</xref>, <xref rid="jah32448-bib-0034" ref-type="ref">34</xref> We modified the Seattle Questionnaire<xref rid="jah32448-bib-0035" ref-type="ref">35</xref> to reflect the short treatment period of 1&#x000a0;week when compared to the original assessment over 4&#x000a0;weeks. Frequency of angina attacks and GTN use were documented on a checklist.</p></sec><sec id="jah32448-sec-0018"><title>Statistical Analysis</title><p>In previous randomized studies of add&#x02010;on antianginal medication (amlodipine, organic nitrates, atenolol, ranolazine, ivabradine, or allopurinol)<xref rid="jah32448-bib-0027" ref-type="ref">27</xref>, <xref rid="jah32448-bib-0036" ref-type="ref">36</xref>, <xref rid="jah32448-bib-0037" ref-type="ref">37</xref>, <xref rid="jah32448-bib-0038" ref-type="ref">38</xref>, <xref rid="jah32448-bib-0039" ref-type="ref">39</xref> the mean difference in time to 1&#x02010;mm ST depression between the active and placebo groups was &#x02248;50&#x000a0;seconds. The SD in crossover studies was &#x02248;80 to 90&#x000a0;seconds.<xref rid="jah32448-bib-0036" ref-type="ref">36</xref>, <xref rid="jah32448-bib-0040" ref-type="ref">40</xref>, <xref rid="jah32448-bib-0041" ref-type="ref">41</xref>, <xref rid="jah32448-bib-0042" ref-type="ref">42</xref> Based on a mean treatment difference of 30&#x000a0;seconds and a SD of 80&#x000a0;seconds with a type I error of 5% and statistical power 80%, we would require 58 patients. To allow for dropouts we planned to randomize 70 patients. We sought to recruit a minimum of 20 patients for the secondary end point of DSE peak systolic velocity, and its sample sizing is described elsewhere.<xref rid="jah32448-bib-0028" ref-type="ref">28</xref>
</p><p>The within&#x02010;patient differences in primary and secondary efficacy end points were assumed to follow a normal distribution. The analysis followed recommendations by Senn<xref rid="jah32448-bib-0043" ref-type="ref">43</xref> for a 2&#x02010;treatment and 2&#x02010;period crossover trial analysis. A general linear model was constructed with the following factors included: patient (as a random effect), period, and treatment (both as fixed effects). Treatment efficacy was estimated as the treatment effect estimate from the model with a 95% confidence interval and the hypothesis of 0 effect tested (5% significance level). An interaction term between treatment and period was included to assess the possibility of a carryover effect. Where this was statistically significant (<italic>P</italic>&#x0003c;0.05), the treatment effect estimate was also provided with this interaction included in the model. The subgroup analysis (which was not defined before the analysis) was carried out in patients not on proton pump inhibitors or H<sub>2</sub> blockers. The assumption of a normal distribution was checked via a graphic inspection of the residuals. All analyses were carried out in SAS version 9.3 (SAS Institute, Cary, NC) by a trial statistician who conducted and reported the analyses subgroup blind.</p></sec></sec><sec id="jah32448-sec-0019"><title>Results</title><sec id="jah32448-sec-0020"><title>Recruitment and Baseline Characteristics</title><p>More than 1600 patients with a diagnosis of angina were invited to participate. Following telephone or clinic interview only 213 potentially suitable patients gave informed consent and were invited for detailed screening investigations. Of these 70 patients were found to be eligible and were randomized (Figure&#x000a0;<xref rid="jah32448-fig-0001" ref-type="fig">1</xref>, Table&#x000a0;<xref rid="jah32448-tbl-0001" ref-type="table-wrap">1</xref>).<xref rid="jah32448-bib-0044" ref-type="ref">44</xref> With overall 93.6% of patients taking all their capsules correctly as prescribed (131 out of 140 treatment periods) the compliance was high. All patients attending for their final day visit took their last capsules in the morning as planned (Data <xref rid="jah32448-sup-0001" ref-type="supplementary-material">S1</xref> and Table&#x000a0;<xref rid="jah32448-sup-0001" ref-type="supplementary-material">S1</xref>).</p><table-wrap id="jah32448-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographics</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Mean (SD) or n (%)</th><th align="left" valign="top" rowspan="1" colspan="1">All Subjects</th><th align="left" valign="top" rowspan="1" colspan="1">Nitrate First (n=36)</th><th align="left" valign="top" rowspan="1" colspan="1">Placebo First (n=34)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, y</td><td align="left" rowspan="1" colspan="1">67.3 (7.7)</td><td align="left" rowspan="1" colspan="1">66.5 (7.9)</td><td align="left" rowspan="1" colspan="1">68.3 (7.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Height, cm</td><td align="left" rowspan="1" colspan="1">168.0 (8.3)</td><td align="left" rowspan="1" colspan="1">169.8 (8.1)</td><td align="left" rowspan="1" colspan="1">166.2 (8.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight, kg</td><td align="left" rowspan="1" colspan="1">80.8 (13.6)</td><td align="left" rowspan="1" colspan="1">84.0 (14.6)</td><td align="left" rowspan="1" colspan="1">77.5 (11.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI</td><td align="left" rowspan="1" colspan="1">28.6 (4.0)</td><td align="left" rowspan="1" colspan="1">29.1 (4.6)</td><td align="left" rowspan="1" colspan="1">28.0 (3.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">LVEF (%)</td><td align="left" rowspan="1" colspan="1">59.5 (7.1)</td><td align="left" rowspan="1" colspan="1">59.8 (6.8)</td><td align="left" rowspan="1" colspan="1">59.2 (7.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic BP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">140.1 (18.1)</td><td align="left" rowspan="1" colspan="1">137.2 (17.9)</td><td align="left" rowspan="1" colspan="1">143.3 (18.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic BP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">79.4 (10.2)</td><td align="left" rowspan="1" colspan="1">78.9 (10.7)</td><td align="left" rowspan="1" colspan="1">80.0 (10.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart rate, bpm</td><td align="left" rowspan="1" colspan="1">61.9 (12.3)</td><td align="left" rowspan="1" colspan="1">60.8 (12.7)</td><td align="left" rowspan="1" colspan="1">63.2 (12.0)</td></tr><tr><td align="left" colspan="4" rowspan="1">Sex</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">52 (74%)</td><td align="left" rowspan="1" colspan="1">31 (86%)</td><td align="left" rowspan="1" colspan="1">21 (62%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">18 (26%)</td><td align="left" rowspan="1" colspan="1">5 (14%)</td><td align="left" rowspan="1" colspan="1">13 (38%)</td></tr><tr><td align="left" colspan="4" rowspan="1">CCS class<xref ref-type="fn" rid="jah32448-note-0002">a</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">29 (41%)</td><td align="left" rowspan="1" colspan="1">16 (44%)</td><td align="left" rowspan="1" colspan="1">13 (38%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">34 (49%)</td><td align="left" rowspan="1" colspan="1">17 (47%)</td><td align="left" rowspan="1" colspan="1">17 (50%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">7 (10%)</td><td align="left" rowspan="1" colspan="1">3 (9%)</td><td align="left" rowspan="1" colspan="1">4 (12%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" colspan="4" rowspan="1">Ischemia test</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Angio only</td><td align="left" rowspan="1" colspan="1">29 (41%)</td><td align="left" rowspan="1" colspan="1">16 (44%)</td><td align="left" rowspan="1" colspan="1">13 (38%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Angio and DSE</td><td align="left" rowspan="1" colspan="1">30 (43%)</td><td align="left" rowspan="1" colspan="1">14 (39%)</td><td align="left" rowspan="1" colspan="1">16 (47%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Angio, DSE, and MPI</td><td align="left" rowspan="1" colspan="1">3 (4%)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">3 (9%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Angio and MPI</td><td align="left" rowspan="1" colspan="1">2 (3%)</td><td align="left" rowspan="1" colspan="1">1 (3%)</td><td align="left" rowspan="1" colspan="1">1 (3%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">DSE only</td><td align="left" rowspan="1" colspan="1">6 (9%)</td><td align="left" rowspan="1" colspan="1">5 (14%)</td><td align="left" rowspan="1" colspan="1">1 (3%)</td></tr><tr><td align="left" colspan="4" rowspan="1">Vessel disease</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Single vessel</td><td align="left" rowspan="1" colspan="1">23 (33%)</td><td align="left" rowspan="1" colspan="1">10 (28%)</td><td align="left" rowspan="1" colspan="1">13 (38%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2 vessels</td><td align="left" rowspan="1" colspan="1">13 (19%)</td><td align="left" rowspan="1" colspan="1">8 (22%)</td><td align="left" rowspan="1" colspan="1">5 (15%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">3 vessels</td><td align="left" rowspan="1" colspan="1">12 (17%)</td><td align="left" rowspan="1" colspan="1">7 (19%)</td><td align="left" rowspan="1" colspan="1">5 (15%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Residual disease<xref ref-type="fn" rid="jah32448-note-0003">b</xref>
</td><td align="left" rowspan="1" colspan="1">17 (24%)</td><td align="left" rowspan="1" colspan="1">7 (19%)</td><td align="left" rowspan="1" colspan="1">10 (29%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No angiography</td><td align="left" rowspan="1" colspan="1">5 (7%)</td><td align="left" rowspan="1" colspan="1">4 (11%)</td><td align="left" rowspan="1" colspan="1">1 (3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous MI</td><td align="left" rowspan="1" colspan="1">29 (41%)</td><td align="left" rowspan="1" colspan="1">13 (36%)</td><td align="left" rowspan="1" colspan="1">16 (47%)</td></tr><tr><td align="left" rowspan="1" colspan="1">HTN</td><td align="left" rowspan="1" colspan="1">36 (51%)</td><td align="left" rowspan="1" colspan="1">19 (53%)</td><td align="left" rowspan="1" colspan="1">17 (50%)</td></tr><tr><td align="left" rowspan="1" colspan="1">DM</td><td align="left" rowspan="1" colspan="1">21 (30%)</td><td align="left" rowspan="1" colspan="1">7 (19%)</td><td align="left" rowspan="1" colspan="1">14 (41%)</td></tr><tr><td align="left" rowspan="1" colspan="1">PAD</td><td align="left" rowspan="1" colspan="1">12 (17%)</td><td align="left" rowspan="1" colspan="1">6 (17%)</td><td align="left" rowspan="1" colspan="1">6 (18%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Stroke or TIA</td><td align="left" rowspan="1" colspan="1">6 (9%)</td><td align="left" rowspan="1" colspan="1">2 (6%)</td><td align="left" rowspan="1" colspan="1">4 (12%)</td></tr><tr><td align="left" colspan="4" rowspan="1">Smoker</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Never</td><td align="left" rowspan="1" colspan="1">32 (46%)</td><td align="left" rowspan="1" colspan="1">18 (50%)</td><td align="left" rowspan="1" colspan="1">14 (41%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Ex&#x02010;smoker</td><td align="left" rowspan="1" colspan="1">35 (51%)</td><td align="left" rowspan="1" colspan="1">17 (47%)</td><td align="left" rowspan="1" colspan="1">18 (53%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Current</td><td align="left" rowspan="1" colspan="1">2 (3%)</td><td align="left" rowspan="1" colspan="1">1 (3%)</td><td align="left" rowspan="1" colspan="1">1 (3%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Missing</td><td align="left" rowspan="1" colspan="1">1 (1%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1 (3%)</td></tr><tr><td align="left" colspan="4" rowspan="1">Previous revascularization</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">39 (56%)</td><td align="left" rowspan="1" colspan="1">24 (67%)</td><td align="left" rowspan="1" colspan="1">15 (44%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">PCI</td><td align="left" rowspan="1" colspan="1">16 (23%)</td><td align="left" rowspan="1" colspan="1">5 (14%)</td><td align="left" rowspan="1" colspan="1">11 (32%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">CABG</td><td align="left" rowspan="1" colspan="1">8 (11%)</td><td align="left" rowspan="1" colspan="1">4 (11%)</td><td align="left" rowspan="1" colspan="1">4 (12%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">PCI and CABG</td><td align="left" rowspan="1" colspan="1">7 (10%)</td><td align="left" rowspan="1" colspan="1">3 (8%)</td><td align="left" rowspan="1" colspan="1">4 (12%)</td></tr><tr><td align="left" colspan="4" rowspan="1">Baseline medication</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Aspirin</td><td align="left" rowspan="1" colspan="1">67 (96%)</td><td align="left" rowspan="1" colspan="1">34 (94%)</td><td align="left" rowspan="1" colspan="1">33 (97%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x003b2;&#x02010;Blocker</td><td align="left" rowspan="1" colspan="1">52 (74%)<xref ref-type="fn" rid="jah32448-note-0004">c</xref>
</td><td align="left" rowspan="1" colspan="1">29 (81%)</td><td align="left" rowspan="1" colspan="1">23 (68%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Long&#x02010;acting organic nitrate</td><td align="left" rowspan="1" colspan="1">27 (39%)<xref ref-type="fn" rid="jah32448-note-0005">d</xref>
</td><td align="left" rowspan="1" colspan="1">15 (42%)</td><td align="left" rowspan="1" colspan="1">12 (35%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Ivabridine</td><td align="left" rowspan="1" colspan="1">2 (3%)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2 (6%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Calcium channel blocker</td><td align="left" rowspan="1" colspan="1">24 (34%)</td><td align="left" rowspan="1" colspan="1">11 (31%)</td><td align="left" rowspan="1" colspan="1">13 (38%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Nicorandil</td><td align="left" rowspan="1" colspan="1">13 (19%)</td><td align="left" rowspan="1" colspan="1">4 (11%)</td><td align="left" rowspan="1" colspan="1">9 (26%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Statin</td><td align="left" rowspan="1" colspan="1">62 (89%)</td><td align="left" rowspan="1" colspan="1">31 (86%)</td><td align="left" rowspan="1" colspan="1">31 (91%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">ACE&#x02010;I</td><td align="left" rowspan="1" colspan="1">25 (36%)</td><td align="left" rowspan="1" colspan="1">16 (44%)</td><td align="left" rowspan="1" colspan="1">9 (26%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">ARB</td><td align="left" rowspan="1" colspan="1">13 (19%)</td><td align="left" rowspan="1" colspan="1">3 (8%)</td><td align="left" rowspan="1" colspan="1">10 (29%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">PPI</td><td align="left" rowspan="1" colspan="1">24 (34%)</td><td align="left" rowspan="1" colspan="1">12 (33%)</td><td align="left" rowspan="1" colspan="1">12 (35%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">H<sub>2</sub> blocker</td><td align="left" rowspan="1" colspan="1">3 (4%)</td><td align="left" rowspan="1" colspan="1">1 (3%)</td><td align="left" rowspan="1" colspan="1">2 (6%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">60 (86%)</td><td align="left" rowspan="1" colspan="1">33 (92%)</td><td align="left" rowspan="1" colspan="1">27 (79%)</td></tr></tbody></table><table-wrap-foot><fn id="jah32448-note-0001"><p>ACE&#x02010;I indicates angiotensin&#x02010;converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass graft; DM, diabetes mellitus; HTN, hypertension; LVEF, left ventricle ejection fraction; MI, myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; PPI, proton pump inhibitor; TIA, transient ischemic attack.</p></fn><fn id="jah32448-note-0002"><label>a</label><p>Canadian Cardiovascular Society Classification of angina severity<xref rid="jah32448-bib-0044" ref-type="ref">44</xref>.</p></fn><fn id="jah32448-note-0003"><label>b</label><p>Previously revascularized multivessel disease with at least single&#x02010;vessel residual disease at time of angiography but unable to rule out progression of disease by the time of study entrance.</p></fn><fn id="jah32448-note-0004"><label>c</label><p>&#x003b2;&#x02010;Blockers were omitted in selected patients (18 [26%]) for 48&#x000a0;hours prior each visit to facilitate dobutamine stress echocardiography; uninterrupted &#x003b2;&#x02010;blocker treatment continued in 34 (49%) patients.</p></fn><fn id="jah32448-note-0005"><label>d</label><p>Oral long&#x02010;acting nitrates were stopped before randomization in all participants.</p></fn></table-wrap-foot></table-wrap></sec><sec id="jah32448-sec-0021"><title>Electrocardiogram Treadmill Test</title><p>The time from the last nitrate capsule ingestion to start of the treadmill test was 154.0 (139.5&#x02010;169.3) minutes (median [interquartile range]). During the nitrate treatment, relative to placebo, there were trends toward reduction of various manifestations of ischemia including time to 1&#x02010;mm ST depression, time to onset of chest pain, and total exercise time (Figure&#x000a0;<xref rid="jah32448-fig-0002" ref-type="fig">2</xref>). However, only changes in total exercise time were statistically significant (median [95% confidence interval] 760.9 [719.5, 802.2] versus 744.4 [702.4, 786.4] seconds, <italic>P</italic>=0.04), whereas for time to 1&#x02010;mm ST depression (661.2 [618.3, 704.0] versus 645.6 [603.1, 688.0] seconds, nitrate versus placebo, <italic>P</italic>=0.10). There was a significant treatment and period interaction effect with respect to total exercise time, but inclusion of this interaction term made no material difference to the treatment effect estimate.</p><fig fig-type="Figure" xml:lang="en" id="jah32448-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Exercise treadmill test. Columns display mean&#x000b1;SEM time until either STD or chest pain and duration of exercise. STD indicates ST segment depression.</p></caption><graphic id="nlm-graphic-3" xlink:href="JAH3-6-e006478-g002"/></fig><p>Post hoc subgroup analysis of the primary end point in patients not on proton pump inhibitors or H<sub>2</sub> blockers (n=43) revealed a near&#x02010;significant increased time to 1&#x02010;mm ST depression in the nitrate arm (estimated effect size +21.89&#x000a0;seconds, <italic>P</italic>=0.070) (Table&#x000a0;<xref rid="jah32448-tbl-0002" ref-type="table-wrap">2</xref>).</p><table-wrap id="jah32448-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Efficacy End Points</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">N</th><th align="left" valign="top" rowspan="1" colspan="1">Nitrate Mean (SD)</th><th align="left" valign="top" rowspan="1" colspan="1">Placebo Mean (SD)</th><th align="left" valign="top" rowspan="1" colspan="1">Difference Mean (SD)</th><th align="left" valign="top" rowspan="1" colspan="1">Effect Estimate<xref ref-type="fn" rid="jah32448-note-0007">a</xref> (95% CI)</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic> Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Time to 1&#x02010;mm ST depression (s)</td><td align="left" rowspan="1" colspan="1">67<xref ref-type="fn" rid="jah32448-note-0008">b</xref>
</td><td align="left" rowspan="1" colspan="1">661.2 (179.0)</td><td align="left" rowspan="1" colspan="1">645.6 (177.2)</td><td align="left" rowspan="1" colspan="1">15.6 (80.9)</td><td align="left" rowspan="1" colspan="1">16.21 (&#x02212;3.4 to 35.8)</td><td align="left" rowspan="1" colspan="1">0.104</td></tr><tr><td align="left" rowspan="1" colspan="1">Time to chest pain (s)</td><td align="left" rowspan="1" colspan="1">49</td><td align="left" rowspan="1" colspan="1">576.9 (201.5)</td><td align="left" rowspan="1" colspan="1">563.5 (197.9)</td><td align="left" rowspan="1" colspan="1">13.4 (98.1)</td><td align="left" rowspan="1" colspan="1">13.56 (&#x02212;14.7 to 41.8)</td><td align="left" rowspan="1" colspan="1">0.343</td></tr><tr><td align="left" rowspan="1" colspan="1">Total exercise time (s)</td><td align="left" rowspan="1" colspan="1">67<xref ref-type="fn" rid="jah32448-note-0008">b</xref>
</td><td align="left" rowspan="1" colspan="1">760.9 (172.7)</td><td align="left" rowspan="1" colspan="1">744.4 (175.4)</td><td align="left" rowspan="1" colspan="1">16.5 (69.5)</td><td align="left" rowspan="1" colspan="1">
17.53 (0.6&#x02010;34.3)<break/>
18.33 (1.5&#x02010;35.2)
</td><td align="left" rowspan="1" colspan="1">
0.041<break/>
0.033
</td></tr><tr><td align="left" rowspan="1" colspan="1">Global peak systolic velocity (% increase)</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">73.11 (33.1)</td><td align="left" rowspan="1" colspan="1">72.6 (31.7)</td><td align="left" rowspan="1" colspan="1">0.43 (31.0)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.23 (&#x02212;13.1 to 12.6)</td><td align="left" rowspan="1" colspan="1">0.972</td></tr><tr><td align="left" rowspan="1" colspan="1">Ischemic segment peak systolic velocity (% increase)</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">64.9 (43.4)</td><td align="left" rowspan="1" colspan="1">60.8 (36.4)</td><td align="left" rowspan="1" colspan="1">4.08 (29.2)</td><td align="left" rowspan="1" colspan="1">5.14 (&#x02212;15.5 to 25.8)</td><td align="left" rowspan="1" colspan="1">0.623</td></tr><tr><td align="left" rowspan="1" colspan="1">Seattle questionnaire score</td><td align="left" rowspan="1" colspan="1">64</td><td align="left" rowspan="1" colspan="1">101.8 (11.2)</td><td align="left" rowspan="1" colspan="1">102.7 (10.9)</td><td align="left" char=" " rowspan="1" colspan="1">&#x02212;0.9 (8.6)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.90 (&#x02212;3.0 to 1.2)</td><td align="left" rowspan="1" colspan="1">0.406</td></tr><tr><td align="left" rowspan="1" colspan="1">Angina attack episodes</td><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1">1.2 (2.5)</td><td align="left" rowspan="1" colspan="1">1.1 (2.2)</td><td align="left" rowspan="1" colspan="1">0.07 (1.4)</td><td align="left" rowspan="1" colspan="1">
0.07 (&#x02212;0.30 to 0.43)<break/>
0.06 (&#x02212;0.30 to 0.43)
</td><td align="left" rowspan="1" colspan="1">
0.712<break/>
0.730
</td></tr><tr><td align="left" rowspan="1" colspan="1">GTN use</td><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1">0.6 (1.7)</td><td align="left" rowspan="1" colspan="1">0.5 (1.4)</td><td align="left" rowspan="1" colspan="1">0.09 (1.1)</td><td align="left" rowspan="1" colspan="1">
0.09 (&#x02212;0.1 to 0.3)<break/>
0.09 (&#x02212;0.18 to 0.37)
</td><td align="left" rowspan="1" colspan="1">
0.514<break/>
0.490
</td></tr><tr><td align="left" colspan="7" rowspan="1">Not taking PPI or H<sub>2</sub> receptor blockers</td></tr><tr><td align="left" rowspan="1" colspan="1">Time to 1&#x02010;mm ST depression (s)</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">662.1 (174.3)</td><td align="left" rowspan="1" colspan="1">641.0 (170.6)</td><td align="left" rowspan="1" colspan="1">21.0 (76.9)</td><td align="left" rowspan="1" colspan="1">21.8 (&#x02212;1.6 to 45.4)</td><td align="left" rowspan="1" colspan="1">0.070</td></tr></tbody></table><table-wrap-foot><fn id="jah32448-note-0006"><p>CI indicates confidence interval; GTN, glyceryl trinitrate; PPI, proton pump inhibitor.</p></fn><fn id="jah32448-note-0007"><label>a</label><p>From linear model including period effect and also a treatment&#x02010;period (ie, &#x0201c;carryover&#x0201d;) effect when this was found to be significant (lower figures).</p></fn><fn id="jah32448-note-0008"><label>b</label><p>Subject 66 missed both periods (withdrawn due to medication error); subject 46 (withdrawn due to nausea), and subject 181 missing second period (limiting chest pain before reaching 1&#x02010;mm STD).</p></fn></table-wrap-foot></table-wrap></sec><sec id="jah32448-sec-0022"><title>Dobutamine Stress Echocardiography</title><p>Fifty&#x02010;three patients underwent a screening DSE, 25 of whom were enrolled into the DSE arm. Change in global systolic velocity (baseline to peak) was not significantly altered by nitrate treatment (<italic>P</italic>=0.972) or when only ischemic segments were analyzed (<italic>P</italic>=0.623) (Table&#x000a0;<xref rid="jah32448-tbl-0002" ref-type="table-wrap">2</xref>).</p></sec><sec id="jah32448-sec-0023"><title>Modified Seattle Questionnaire, GTN Use, and Angina Frequency</title><p>There was no significant difference in the Modified Seattle Questionnaire score, GTN use, or in angina frequency between the treatment arms (Table&#x000a0;<xref rid="jah32448-tbl-0002" ref-type="table-wrap">2</xref>).</p></sec><sec id="jah32448-sec-0024"><title>Bloods</title><p>The time from the last nitrate capsule ingestion on the morning of the visit to the blood test was 135.0 (129.3&#x02010;157.5) minutes (median [IQR]). Compared with placebo the nitrate&#x02010;treated arm had significantly higher plasma nitrate (mean [SD] 18.3 [6.5] versus 297.6 [164.3] &#x003bc;mol/L, <italic>P</italic>&#x0003c;0.0001) and nitrite (mean [SD] 346 [124] versus 552 [320] nmol/L, <italic>P</italic>=0.003; Figure&#x000a0;<xref rid="jah32448-fig-0003" ref-type="fig">3</xref>).</p><fig fig-type="Figure" xml:lang="en" id="jah32448-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Plasma levels of (A) nitrate, (B) nitrite, (C) VEGF, and (D) sFlt&#x02010;1. Data are displayed as mean&#x000b1;SEM. sFlt indicates soluble fms&#x02010;like tyrosine kinase receptor; VEGF, vascular endothelial growth factor.</p></caption><graphic id="nlm-graphic-5" xlink:href="JAH3-6-e006478-g003"/></fig><p>There was no significant difference in angiogenic markers between the placebo and nitrate arms (mean [SD] vascular endothelial growth factor, 66.5 [65.3] versus 76.1 [87.2] pg/mL, <italic>P</italic>=0.347; mean [SD] soluble fms&#x02010;like tyrosine kinase receptor&#x02010;1, 216.1 [160.4] versus 182.0 [62.2] pg/mL, 0.321; Figure&#x000a0;<xref rid="jah32448-fig-0003" ref-type="fig">3</xref>).</p></sec><sec id="jah32448-sec-0025"><title>Blood Pressure</title><p>There was no difference in BP obtained at rest (nitrate versus placebo, systolic BP 132.4 [18.2] versus 131.3 [22.8] mm&#x000a0;Hg, <italic>P</italic>=0.670; diastolic BP 76.3 [11.0] versus 76.9 [13.2] mm&#x000a0;Hg, <italic>P</italic>=0.519) or at peak exercise (nitrate versus placebo, systolic BP 175.3 [26.0] versus 173.0 [27.4] mm&#x000a0;Hg, <italic>P</italic>=0.427; diastolic BP 76.5 [12.2] versus 75.6 [12.6] mm&#x000a0;Hg, <italic>P</italic>=0.626).</p></sec><sec id="jah32448-sec-0026"><title>Adverse Events</title><p>In general the treatment was tolerated well. Gastrointestinal side effects were more common in the nitrate arm (Table&#x000a0;<xref rid="jah32448-tbl-0003" ref-type="table-wrap">3</xref>). One patient reported severe vomiting following the capsule intake for 3 consecutive mornings and was withdrawn from the study.</p><table-wrap id="jah32448-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Adverse Events</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">n (%)</th><th align="left" valign="top" rowspan="1" colspan="1">Nitrate</th><th align="left" valign="top" rowspan="1" colspan="1">Placebo</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Nausea/abdominal cramps</td><td align="left" rowspan="1" colspan="1">6 (9%)</td><td align="left" rowspan="1" colspan="1">3 (4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Vomiting</td><td align="left" rowspan="1" colspan="1">3 (4%)</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Dry mouth</td><td align="left" rowspan="1" colspan="1">1 (1%)</td><td align="left" rowspan="1" colspan="1">1 (1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Tiredness</td><td align="left" rowspan="1" colspan="1">1 (1%)</td><td align="left" rowspan="1" colspan="1">1 (1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hot flushes</td><td align="left" rowspan="1" colspan="1">1 (1%)</td><td align="left" rowspan="1" colspan="1">1 (1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Headache</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">3 (4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Loose stool</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1 (1%)</td></tr></tbody></table></table-wrap></sec></sec><sec id="jah32448-sec-0027"><title>Discussion</title><p>Sodium nitrate treatment added to other background medication failed to reach the predefined level of statistical significance for the difference in the primary end point (time to 1&#x02010;mm ST depression). However, there was a trend to improvement in this outcome and a statistically significant increase in the predefined secondary end point, total exercise time, supporting a modest anti&#x02010;ischemic effect. All treadmill test parameters trended to improve performance with nitrate supplementation (Figure&#x000a0;<xref rid="jah32448-fig-0002" ref-type="fig">2</xref>). On a post hoc analysis there was a strong positive correlation among the time to 1&#x02010;mm ST depression, total exercise time, and time to chest pain onset (Pearson r varied between 0.6 and 0.7, all <italic>P</italic>&#x0003c;0.001, Figures <xref rid="jah32448-sup-0001" ref-type="supplementary-material">S1 through S3</xref>).</p><p>The observed SD of difference in means of time to 1&#x02010;mm ST depression was in line with the SD used for our sample size calculations. The sample size calculations assumed a mean difference in this primary outcome measure of 30&#x000a0;seconds based on previous trials in the field. Although the estimate of effect was indicative of a benefit of nitrate (+16.21 [&#x02212;3.4 to +35.8] seconds, effect estimate [95% confidence interval]), the difference did not reach statistical significance. This may be because there is indeed no benefit or may reflect a more modest benefit than we had assumed in our sample size calculations. The significant increase in total exercise time may support the latter conclusion. The population size that we studied was substantially larger than those of previous crossover studies investigating the effects of inorganic nitrate on exercise or BP behavior, where typically cohorts of sizes n=8 to 15 were sufficient to show effects.<xref rid="jah32448-bib-0011" ref-type="ref">11</xref>, <xref rid="jah32448-bib-0021" ref-type="ref">21</xref> Although there was a trend to delay ischemia in the nitrate&#x02010;treated group, the increase of exercise capacity in our population may possibly&#x000a0;be due to an improvement of skeletal muscle function rather than a direct anti&#x02010;ischemic cardiac effect. Improvement of skeletal muscle oxygen handling and mitochondrial efficiency on exercise was previously described in healthy volunteers.<xref rid="jah32448-bib-0008" ref-type="ref">8</xref>, <xref rid="jah32448-bib-0009" ref-type="ref">9</xref>, <xref rid="jah32448-bib-0010" ref-type="ref">10</xref>, <xref rid="jah32448-bib-0011" ref-type="ref">11</xref>, <xref rid="jah32448-bib-0012" ref-type="ref">12</xref> Recently the SIRT3&#x02010;AMPK&#x02010;glut4 activation pathway, which is associated with improved glucose handling in human skeletal muscle, was demonstrated in volunteers with metabolic syndrome.<xref rid="jah32448-bib-0045" ref-type="ref">45</xref> Coggan et&#x000a0;al demonstrated in systolic heart failure patients that a single dose of nitrate&#x02010;rich beetroot juice led to a significant increase of skeletal muscle power.<xref rid="jah32448-bib-0046" ref-type="ref">46</xref> Furthermore, Zamani et&#x000a0;al recently reported improved exercise capacity in heart failure patients with preserved ejection fraction.<xref rid="jah32448-bib-0047" ref-type="ref">47</xref> The effect was mainly due to reduction of vascular resistance and increase of cardiac output on exercise.</p><p>In our study population there were no differences in Modified Seattle Questionnaire, use of GTN, or angina between treatment arms. It has to be noted that the latter 3 secondary outcomes were always felt to be particularly weak end points for this particular study design; nevertheless, we felt they should be reported. The treatment arms were short, and angina episodes and GTN use were less frequently reported than expected during the individual test weeks (&#x0003c;1 per treatment period, Table&#x000a0;<xref rid="jah32448-tbl-0002" ref-type="table-wrap">2</xref>).</p><p>Nowadays, revascularization is performed rapidly after listing for a procedure. Therefore, we elected a relatively short treatment period (7 to 10&#x000a0;days) to avoid interference with potential clinical revascularization plans. We cannot exclude a greater effect with a longer treatment period.</p><p>Many of our patients were elderly, had multivessel disease, and over years adapted their lifestyle to avoid angina. There was a clear discrepancy between their infrequent subjective reporting of angina despite objective severe disease, limiting chest pain on treadmill testing, and electrocardigraphic and echocardiographic evidence of inducible ischemia on functional testing. Even patients who on screening in their own description belonged to Canadian Cardiovascular Society class III were objectively limited on exercise at low workload but reported only 1 or even no angina episodes and little GTN use during the test weeks later. Consequently, the study was underpowered for these secondary end points. Despite previous reports of proangiogenic markers in skeletal muscle (animal model) and plasma in healthy volunteers, we observed no increase in systemic proangiogenic markers in our angina population.</p><p>In our study 7&#x000a0;mmol (600&#x000a0;mg) of sodium nitrate was given daily for 1&#x000a0;week. Previously, single doses as low as 3.5&#x000a0;mmol nitrate were effective in lowering blood pressure when given to drug&#x02010;naive grade 1 hypertensive volunteers.<xref rid="jah32448-bib-0030" ref-type="ref">30</xref> A single oral dose of 4&#x000a0;mmol potassium nitrate was sufficient to lower blood pressure in healthy volunteers.<xref rid="jah32448-bib-0020" ref-type="ref">20</xref> A recent meta&#x02010;analysis showed that doses ranging from 300 to 600&#x000a0;mg nitrate (either in the form of beetroot juice or sodium nitrate) suggested a significant moderate benefit on time to exhaustion.<xref rid="jah32448-bib-0011" ref-type="ref">11</xref> Larsen et&#x000a0;al demonstrated in young healthy volunteers that a daily dose of 0.1&#x000a0;mmol/kg given for 3 consecutive days improved mitochondrial efficiency in skeletal muscle.<xref rid="jah32448-bib-0010" ref-type="ref">10</xref> The dose used in our study is several times higher than an average Western diet intake, which contains &#x02248;100&#x000a0;mg/day.<xref rid="jah32448-bib-0048" ref-type="ref">48</xref> Our patients ingested their last study capsule &#x02248;2 to 3&#x000a0;hours before their treadmill test. This corresponds to peak plasma nitrite following oral nitrate absorption and enterosalivary bioconversion to nitrite.<xref rid="jah32448-bib-0019" ref-type="ref">19</xref>, <xref rid="jah32448-bib-0020" ref-type="ref">20</xref>, <xref rid="jah32448-bib-0025" ref-type="ref">25</xref> The increases in plasma nitrate and nitrite are similar to those seen in studies demonstrating a blood pressure&#x02013;lowering effect. Although it is possible that a higher dose might have been more effective, this could also have potentially increased side effects.</p><p>We observed gastrointestinal side effects (usually mild) relatively frequently (Table&#x000a0;<xref rid="jah32448-tbl-0003" ref-type="table-wrap">3</xref>). There were no reports of gastrointestinal adverse events in a meta&#x02010;analysis of 17 studies assessing nitrate's effects on BP and another meta&#x02010;analysis of 16 studies assessing its effects on exercise capacity.<xref rid="jah32448-bib-0011" ref-type="ref">11</xref>, <xref rid="jah32448-bib-0021" ref-type="ref">21</xref> However, the majority of these studies were not formal clinical trials of investigational medicinal products requiring reporting of adverse events, and consequently, there might have been underreporting.</p><p>Furthermore, most participants in previous studies were young healthy volunteers. Elderly overweight, sedentary patients on polypharmacy are more likely to suffer from chronic esophageal reflux disease or peptic ulcerative disease. In line with this, a significant proportion (38%) of our angina patients were taking proton pump or H<sub>2</sub> inhibitors. Upper gastrointestinal side effects were well known when much higher doses of inorganic nitrates or nitrites were used for angina treatment at the beginning of the 20th century.<xref rid="jah32448-bib-0049" ref-type="ref">49</xref>
</p><p>We did not observe the BP&#x02010;lowering effect previously observed in healthy young volunteers<xref rid="jah32448-bib-0019" ref-type="ref">19</xref> and in nonobese drug&#x02010;naive grade I hypertensives,<xref rid="jah32448-bib-0030" ref-type="ref">30</xref> but other studies have suggested that this effect may be absent in obese elderly subjects with insulin resistance.<xref rid="jah32448-bib-0050" ref-type="ref">50</xref>, <xref rid="jah32448-bib-0051" ref-type="ref">51</xref> Our study population had end&#x02010;organ cardiovascular disease and high BMI (28.6&#x000b1;4.1) kg/m<sup>2</sup>; most were hypertensives and were taking regular background medication.</p><p>Another important factor is the polypharmacy these patients were on. Gilchrist et&#x000a0;al studied patients with type 2 diabetes mellitus and hypertension (many on antihypertensives), and, unlike with studies in healthy volunteers, they observed no effect of nitrate therapy on the oxygen cost of submaximal exercise.<xref rid="jah32448-bib-0050" ref-type="ref">50</xref> Our study patients were frequently on antihypertensive treatment (Table&#x000a0;<xref rid="jah32448-tbl-0001" ref-type="table-wrap">1</xref>). In metabolic syndrome, a dysregulation of nitric oxide signaling may interfere with efficacy of some conventional drugs used; on the other hand, certain medications such as statins, angiotensin&#x02010;converting enzyme inhibitors, angiotensin receptor blockers, or &#x003b2; blockers may exert their therapeutic effects via modulation of nitric oxide signaling.<xref rid="jah32448-bib-0052" ref-type="ref">52</xref> Under such circumstances traditional medications may weaken the effect of nitrate supplementation. This may be a reason why other investigators saw more pronounced vasodilator effects even in the elderly population when they chose fairly healthy subjects with no background of antihypertensive drugs. Medications or other underlying medical conditions that alter the gastric pH,<xref rid="jah32448-bib-0053" ref-type="ref">53</xref>, <xref rid="jah32448-bib-0054" ref-type="ref">54</xref>, <xref rid="jah32448-bib-0055" ref-type="ref">55</xref> saliva production, oral bacteria, or intestinal bacterial flora may affect the effectiveness of nitrate treatment. A subgroup analysis of patients who were naive of stomach acid&#x02013;suppressing medication in our study showed a stronger trend to anti&#x02010;ischemic efficacy in our study (see Table&#x000a0;<xref rid="jah32448-tbl-0002" ref-type="table-wrap">2</xref>), supporting the recent concern that antacids may impact on the efficiency of inorganic nitrate&#x02013;based management in humans<xref rid="jah32448-bib-0054" ref-type="ref">54</xref>, <xref rid="jah32448-bib-0055" ref-type="ref">55</xref> by preventing the bioactivation of nitrite to nitrous acid (HNO<sub>2</sub>) in the stomach.<xref rid="jah32448-bib-0056" ref-type="ref">56</xref>
</p><p>It is difficult to prove antianginal effects in patients on multiple background medications. Although our findings indicate at most modest effects of nitrate when it is given as add&#x02010;on therapy, we cannot rule out a stronger benefit if given as a monotherapy. However, we believe that the strength of our study lies in the analysis of real&#x02010;life clinical scenarios including patients with multiple comorbidities on polypharmacy. The crossover design made it possible to account for this variation. Chronic angina patients would be very unlikely to be treated with inorganic nitrate monotherapy in the presence of potent first&#x02010;line anti&#x02010;anginals, and similar studies would be ethically difficult to defend. In this context, it is quite exciting that a dietary treatment strategy has modest benefits on exercise capacity without lowering BP or heart rate. No current standard antianginal medication offers any prognostic benefit for the patients. In the context of a trend to increased time to 1&#x02010;mm ST depression and a significantly increased total exercise capacity together with the well&#x02010;described prognostic benefit of a nitrate&#x02010;rich Mediterranean diet or the fruit&#x02010; and vegetable&#x02010;rich DASH diet,<xref rid="jah32448-bib-0002" ref-type="ref">2</xref>, <xref rid="jah32448-bib-0048" ref-type="ref">48</xref>, <xref rid="jah32448-bib-0057" ref-type="ref">57</xref> it appears appropriate to recommend that angina patients adhere to the above diets. Although the treatment period was relatively short (in order to avoid interference of natural disease progression on the outcome analysis in this crossover design), the supplementation resulted in better exercise performance. The results of a longer&#x02010;term supplementation will need to be established in further studies. Although rare and usually mild, nausea and vomiting were reported. Patients ought to be alerted to this possible adverse effect.</p></sec><sec id="jah32448-sec-0029"><title>Sources of Funding</title><p>The study was funded by the Medical Research Council, (UK) grant number G1001536.</p></sec><sec id="jah32448-sec-0030"><title>Disclosures</title><p>None.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="jah32448-sup-0001"><caption><p>
<bold>Data S1.</bold> Compliance</p><p>
<bold>Table&#x000a0;S1.</bold> Compliance</p><p>
<bold>Figure&#x000a0;S1.</bold> Correlation between the differences of paired treatment arms of total exercise time and time to 1&#x02010;mm ST depression (STD).</p><p>
<bold>Figure&#x000a0;S2.</bold> Correlation between the differences of paired treatment arms of total exercise time and time to chest pain onset.</p><p>
<bold>Figure&#x000a0;S3.</bold> Correlation between the differences of paired treatment arms of time to chest pain onset and time to 1&#x02010;mm ST depression (STD).</p></caption><media xlink:href="JAH3-6-e006478-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="jah32448-sec-0028"><title>Acknowledgments</title><p>We are very grateful to Amanda Cardy (Scottish Primary Research Network) for her help with recruitment from primary care centers. Further thanks are to Maggie Bruce, Val Harries, and Frances Adamson for their assistance with study recruitment. The last and foremost thanks are to all participating patients. The Trial Steering Committee consisted of Awsan Noman, Michael Frenneaux, Konstantin Schwarz, Zaid Mahmood, Frank Thies. The Data Monitoring Committee included Mathew Yuyun, Markus Zeitlinger, and Roger Beadle.</p></ack><ref-list content-type="cited-references" id="jah32448-bibl-0001"><title>References</title><ref id="jah32448-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jah32448-cit-0001">
<string-name>
<surname>Manolis</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Poulimenos</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Ambrosio</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Kallistratos</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Lopez&#x02010;Sendon</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Dechend</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Mancia</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Camm</surname>
<given-names>AJ</given-names>
</string-name>. <article-title>Medical treatment of stable angina: a tailored therapeutic approach</article-title>. <source>Int J Cardiol</source>. <year>2016</year>;<volume>220</volume>:<fpage>445</fpage>&#x02013;<lpage>453</lpage>.<pub-id pub-id-type="pmid">27390968</pub-id></mixed-citation></ref><ref id="jah32448-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jah32448-cit-0002">
<string-name>
<surname>Lundberg</surname>
<given-names>JO</given-names>
</string-name>, <string-name>
<surname>Weitzberg</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Gladwin</surname>
<given-names>MT</given-names>
</string-name>. <article-title>The nitrate&#x02010;nitrite&#x02010;nitric oxide pathway in physiology and therapeutics</article-title>. <source>Nat Rev Drug Discov</source>. <year>2008</year>;<volume>7</volume>:<fpage>156</fpage>&#x02013;<lpage>167</lpage>.<pub-id pub-id-type="pmid">18167491</pub-id></mixed-citation></ref><ref id="jah32448-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jah32448-cit-0003">
<string-name>
<surname>Cosby</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Partovi</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Crawford</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Reiter</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Martyr</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>BK</given-names>
</string-name>, <string-name>
<surname>Waclawiw</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Zalos</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>KT</given-names>
</string-name>, <string-name>
<surname>Shields</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kim&#x02010;Shapiro</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Schechter</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>Cannon</surname>
<given-names>RO</given-names>
<suffix>III</suffix>
</string-name>, <string-name>
<surname>Gladwin</surname>
<given-names>MT</given-names>
</string-name>. <article-title>Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation</article-title>. <source>Nat Med</source>. <year>2003</year>;<volume>9</volume>:<fpage>1498</fpage>&#x02013;<lpage>1505</lpage>.<pub-id pub-id-type="pmid">14595407</pub-id></mixed-citation></ref><ref id="jah32448-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jah32448-cit-0004">
<string-name>
<surname>Maher</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Milsom</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Gunaruwan</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Abozguia</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ahmed</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Weaver</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Ashrafian</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Born</surname>
<given-names>GVR</given-names>
</string-name>, <string-name>
<surname>James</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Frenneaux</surname>
<given-names>MP</given-names>
</string-name>. <article-title>Hypoxic modulation of exogenous nitrite&#x02010;induced vasodilation in humans</article-title>. <source>Circulation</source>. <year>2008</year>;<volume>117</volume>:<fpage>670</fpage>&#x02013;<lpage>677</lpage>.<pub-id pub-id-type="pmid">18212289</pub-id></mixed-citation></ref><ref id="jah32448-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jah32448-cit-0005">
<string-name>
<surname>Ingram</surname>
<given-names>TE</given-names>
</string-name>, <string-name>
<surname>Pinder</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Bailey</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Fraser</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>James</surname>
<given-names>PE</given-names>
</string-name>. <article-title>Low&#x02010;dose sodium nitrite vasodilates hypoxic human pulmonary vasculature by a means that is not dependent on a simultaneous elevation in plasma nitrite</article-title>. <source>Am J Physiol Heart Circ Physiol</source>. <year>2010</year>;<volume>298</volume>:<fpage>H331</fpage>&#x02013;<lpage>H339</lpage>.<pub-id pub-id-type="pmid">19940079</pub-id></mixed-citation></ref><ref id="jah32448-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jah32448-cit-0006">
<string-name>
<surname>Crawford</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Isbell</surname>
<given-names>TS</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Shiva</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Chacko</surname>
<given-names>BK</given-names>
</string-name>, <string-name>
<surname>Schechter</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>Darley&#x02010;Usmar</surname>
<given-names>VM</given-names>
</string-name>, <string-name>
<surname>Kerby</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Lang</surname>
<given-names>JD</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Kraus</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ho</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Gladwin</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>RP</given-names>
</string-name>. <article-title>Hypoxia, red blood cells, and nitrite regulate NO&#x02010;dependent hypoxic vasodilation</article-title>. <source>Blood</source>. <year>2006</year>;<volume>107</volume>:<fpage>566</fpage>&#x02013;<lpage>574</lpage>.<pub-id pub-id-type="pmid">16195332</pub-id></mixed-citation></ref><ref id="jah32448-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jah32448-cit-0007">
<string-name>
<surname>Dejam</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hunter</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Tremonti</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Pluta</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Hon</surname>
<given-names>YY</given-names>
</string-name>, <string-name>
<surname>Grimes</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Partovi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Pelletier</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Oldfield</surname>
<given-names>EH</given-names>
</string-name>, <string-name>
<surname>Cannon</surname>
<given-names>RO</given-names>
<suffix>III</suffix>
</string-name>, <string-name>
<surname>Schechter</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>Gladwin</surname>
<given-names>MT</given-names>
</string-name>. <article-title>Nitrite infusion in humans and nonhuman primates: endocrine effects, pharmacokinetics, and tolerance formation</article-title>. <source>Circulation</source>. <year>2007</year>;<volume>116</volume>:<fpage>1821</fpage>&#x02013;<lpage>1831</lpage>.<pub-id pub-id-type="pmid">17893272</pub-id></mixed-citation></ref><ref id="jah32448-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jah32448-cit-0008">
<string-name>
<surname>Bailey</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Winyard</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Vanhatalo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Blackwell</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>DiMenna</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>Wilkerson</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Tarr</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Benjamin</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>AM</given-names>
</string-name>. <article-title>Dietary nitrate supplementation reduces the O<sub>2</sub> cost of low&#x02010;intensity exercise and enhances tolerance to high&#x02010;intensity exercise in humans</article-title>. <source>J Appl Physiol</source>. <year>2009</year>;<volume>107</volume>:<fpage>1144</fpage>&#x02013;<lpage>1155</lpage>.<pub-id pub-id-type="pmid">19661447</pub-id></mixed-citation></ref><ref id="jah32448-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jah32448-cit-0009">
<string-name>
<surname>Larsen</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>Weitzberg</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Lundberg</surname>
<given-names>JO</given-names>
</string-name>, <string-name>
<surname>Ekblom</surname>
<given-names>B</given-names>
</string-name>. <article-title>Dietary nitrate reduces maximal oxygen consumption while maintaining work performance in maximal exercise</article-title>. <source>Free Radic Biol Med</source>. <year>2010</year>;<volume>48</volume>:<fpage>342</fpage>&#x02013;<lpage>347</lpage>.<pub-id pub-id-type="pmid">19913611</pub-id></mixed-citation></ref><ref id="jah32448-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jah32448-cit-0010">
<string-name>
<surname>Larsen</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>Schiffer</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Borniquel</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sahlin</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ekblom</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Lundberg</surname>
<given-names>JO</given-names>
</string-name>, <string-name>
<surname>Weitzberg</surname>
<given-names>E</given-names>
</string-name>. <article-title>Dietary inorganic nitrate improves mitochondrial efficiency in humans</article-title>. <source>Cell Metab</source>. <year>2011</year>;<volume>13</volume>:<fpage>149</fpage>&#x02013;<lpage>159</lpage>.<pub-id pub-id-type="pmid">21284982</pub-id></mixed-citation></ref><ref id="jah32448-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jah32448-cit-0011">
<string-name>
<surname>Hoon</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Chapman</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Burke</surname>
<given-names>LM</given-names>
</string-name>. <article-title>The effect of nitrate supplementation on exercise performance in healthy individuals: a systematic review and meta&#x02010;analysis</article-title>. <source>Int J Sport Nutr Exerc Metab</source>. <year>2013</year>;<volume>23</volume>:<fpage>522</fpage>&#x02013;<lpage>532</lpage>.<pub-id pub-id-type="pmid">23580439</pub-id></mixed-citation></ref><ref id="jah32448-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jah32448-cit-0012">
<string-name>
<surname>Muggeridge</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Howe</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Spendiff</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Pedlar</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>James</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Easton</surname>
<given-names>C</given-names>
</string-name>. <article-title>A single dose of beetroot juice enhances cycling performance in simulated altitude</article-title>. <source>Med Sci Sports Exerc</source>. <year>2014</year>;<volume>46</volume>:<fpage>143</fpage>&#x02013;<lpage>150</lpage>.<pub-id pub-id-type="pmid">23846159</pub-id></mixed-citation></ref><ref id="jah32448-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jah32448-cit-0013">
<string-name>
<surname>Burwell</surname>
<given-names>LS</given-names>
</string-name>, <string-name>
<surname>Brookes</surname>
<given-names>PS</given-names>
</string-name>. <article-title>Mitochondria as a target for the cardioprotective effects of nitric oxide in ischemia&#x02010;reperfusion injury</article-title>. <source>Antioxid Redox Signal</source>. <year>2008</year>;<volume>10</volume>:<fpage>579</fpage>&#x02013;<lpage>599</lpage>.<pub-id pub-id-type="pmid">18052718</pub-id></mixed-citation></ref><ref id="jah32448-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jah32448-cit-0014">
<string-name>
<surname>Nadtochiy</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Burwell</surname>
<given-names>LS</given-names>
</string-name>, <string-name>
<surname>Brookes</surname>
<given-names>PS</given-names>
</string-name>. <article-title>Cardioprotection and mitochondrial S&#x02010;nitrosation: effects of S&#x02010;nitroso&#x02010;2&#x02010;mercaptopropionyl glycine (SNO&#x02010;MPG) in cardiac ischemia&#x02010;reperfusion injury</article-title>. <source>J Mol Cell Cardiol</source>. <year>2007</year>;<volume>42</volume>:<fpage>812</fpage>&#x02013;<lpage>825</lpage>.<pub-id pub-id-type="pmid">17350035</pub-id></mixed-citation></ref><ref id="jah32448-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jah32448-cit-0015">
<string-name>
<surname>Nadtochiy</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Tompkins</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Brookes</surname>
<given-names>PS</given-names>
</string-name>. <article-title>Different mechanisms of mitochondrial proton leak in ischaemia/reperfusion injury and preconditioning: implications for pathology and cardioprotection</article-title>. <source>Biochem J</source>. <year>2006</year>;<volume>395</volume>:<fpage>611</fpage>&#x02013;<lpage>618</lpage>.<pub-id pub-id-type="pmid">16436046</pub-id></mixed-citation></ref><ref id="jah32448-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jah32448-cit-0016">
<string-name>
<surname>Dezfulian</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Shiva</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Alekseyenko</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Pendyal</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Beiser</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Munasinghe</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Chesley</surname>
<given-names>CF</given-names>
</string-name>, <string-name>
<surname>Vanden Hoek</surname>
<given-names>TL</given-names>
</string-name>, <string-name>
<surname>Gladwin</surname>
<given-names>MT</given-names>
</string-name>. <article-title>Nitrite therapy after cardiac arrest reduces reactive oxygen species generation, improves cardiac and neurological function, and enhances survival via reversible inhibition of mitochondrial complex I</article-title>. <source>Circulation</source>. <year>2009</year>;<volume>120</volume>:<fpage>897</fpage>&#x02013;<lpage>905</lpage>.<pub-id pub-id-type="pmid">19704094</pub-id></mixed-citation></ref><ref id="jah32448-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jah32448-cit-0017">
<string-name>
<surname>Shiva</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sack</surname>
<given-names>MN</given-names>
</string-name>, <string-name>
<surname>Greer</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Duranski</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ringwood</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Burwell</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>MacArthur</surname>
<given-names>PH</given-names>
</string-name>, <string-name>
<surname>Shoja</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Raghavachari</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Calvert</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Brookes</surname>
<given-names>PS</given-names>
</string-name>, <string-name>
<surname>Lefer</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Gladwin</surname>
<given-names>MT</given-names>
</string-name>. <article-title>Nitrite augments tolerance to ischemia/reperfusion injury via the modulation of mitochondrial electron transfer</article-title>. <source>J Exp Med</source>. <year>2007</year>;<volume>204</volume>:<fpage>2089</fpage>&#x02013;<lpage>2102</lpage>.<pub-id pub-id-type="pmid">17682069</pub-id></mixed-citation></ref><ref id="jah32448-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jah32448-cit-0018">
<string-name>
<surname>Rammos</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hendgen&#x02010;Cotta</surname>
<given-names>UB</given-names>
</string-name>, <string-name>
<surname>Sobierajski</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bernard</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kelm</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rassaf</surname>
<given-names>T</given-names>
</string-name>. <article-title>Dietary nitrate reverses vascular dysfunction in older adults with moderately increased cardiovascular risk</article-title>. <source>J Am Coll Cardiol</source>. <year>2014</year>;<volume>63</volume>:<fpage>1584</fpage>&#x02013;<lpage>1585</lpage>.<pub-id pub-id-type="pmid">23994403</pub-id></mixed-citation></ref><ref id="jah32448-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jah32448-cit-0019">
<string-name>
<surname>Webb</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Loukogeorgakis</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Okorie</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Aboud</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Misra</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Rashid</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Miall</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Deanfield</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Benjamin</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>MacAllister</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Hobbs</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Ahluwalia</surname>
<given-names>A</given-names>
</string-name>. <article-title>Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite</article-title>. <source>Hypertension</source>. <year>2008</year>;<volume>51</volume>:<fpage>784</fpage>&#x02013;<lpage>790</lpage>.<pub-id pub-id-type="pmid">18250365</pub-id></mixed-citation></ref><ref id="jah32448-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jah32448-cit-0020">
<string-name>
<surname>Kapil</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Milsom</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Okorie</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Maleki&#x02010;Toyserkani</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Akram</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Rehman</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Arghandawi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Pearl</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Benjamin</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Loukogeorgakis</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>MacAllister</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Hobbs</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Webb</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Ahluwalia</surname>
<given-names>A</given-names>
</string-name>. <article-title>Inorganic nitrate supplementation lowers blood pressure in humans: role for nitrite&#x02010;derived NO</article-title>. <source>Hypertension</source>. <year>2010</year>;<volume>56</volume>:<fpage>274</fpage>&#x02013;<lpage>281</lpage>.<pub-id pub-id-type="pmid">20585108</pub-id></mixed-citation></ref><ref id="jah32448-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jah32448-cit-0021">
<string-name>
<surname>Siervo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lara</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ogbonmwan</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Mathers</surname>
<given-names>JC</given-names>
</string-name>. <article-title>Inorganic nitrate and beetroot juice supplementation reduces blood pressure in adults: a systematic review and meta&#x02010;analysis</article-title>. <source>J Nutr</source>. <year>2013</year>;<volume>143</volume>:<fpage>818</fpage>&#x02013;<lpage>826</lpage>.<pub-id pub-id-type="pmid">23596162</pub-id></mixed-citation></ref><ref id="jah32448-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jah32448-cit-0022">
<string-name>
<surname>Zuckerbraun</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Shiva</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ifedigbo</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Mathier</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Mollen</surname>
<given-names>KP</given-names>
</string-name>, <string-name>
<surname>Rao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bauer</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>JJW</given-names>
</string-name>, <string-name>
<surname>Curtis</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>AMK</given-names>
</string-name>, <string-name>
<surname>Gladwin</surname>
<given-names>MT</given-names>
</string-name>. <article-title>Nitrite potently inhibits hypoxic and inflammatory pulmonary arterial hypertension and smooth muscle proliferation via xanthine oxidoreductase&#x02010;dependent nitric oxide generation</article-title>. <source>Circulation</source>. <year>2010</year>;<volume>121</volume>:<fpage>98</fpage>&#x02013;<lpage>109</lpage>.<pub-id pub-id-type="pmid">20026772</pub-id></mixed-citation></ref><ref id="jah32448-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jah32448-cit-0023">
<string-name>
<surname>Baliga</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Milsom</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Ghosh</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Trinder</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>MacAllister</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Ahluwalia</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hobbs</surname>
<given-names>AJ</given-names>
</string-name>. <article-title>Dietary nitrate ameliorates pulmonary hypertension: cytoprotective role for endothelial nitric oxide synthase and xanthine oxidoreductase</article-title>. <source>Circulation</source>. <year>2012</year>;<volume>125</volume>:<fpage>2922</fpage>&#x02013;<lpage>2932</lpage>.<pub-id pub-id-type="pmid">22572914</pub-id></mixed-citation></ref><ref id="jah32448-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jah32448-cit-0024">
<string-name>
<surname>Hendgen&#x02010;Cotta</surname>
<given-names>UB</given-names>
</string-name>, <string-name>
<surname>Luedike</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Totzeck</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kropp</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schicho</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Stock</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Rammos</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Niessen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Heiss</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lundberg</surname>
<given-names>JO</given-names>
</string-name>, <string-name>
<surname>Weitzberg</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kelm</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rassaf</surname>
<given-names>T</given-names>
</string-name>. <article-title>Dietary nitrate supplementation improves revascularization in chronic ischemia</article-title>. <source>Circulation</source>. <year>2012</year>;<volume>126</volume>:<fpage>1983</fpage>&#x02013;<lpage>1992</lpage>.<pub-id pub-id-type="pmid">22992322</pub-id></mixed-citation></ref><ref id="jah32448-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jah32448-cit-0025">
<string-name>
<surname>Heiss</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Meyer</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Totzeck</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hendgen&#x02010;Cotta</surname>
<given-names>UB</given-names>
</string-name>, <string-name>
<surname>Heinen</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Luedike</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Keymel</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ayoub</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Lundberg</surname>
<given-names>JO</given-names>
</string-name>, <string-name>
<surname>Weitzberg</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kelm</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rassaf</surname>
<given-names>T</given-names>
</string-name>. <article-title>Dietary inorganic nitrate mobilizes circulating angiogenic cells</article-title>. <source>Free Radic Biol Med</source>. <year>2012</year>;<volume>52</volume>:<fpage>1767</fpage>&#x02013;<lpage>1772</lpage>.<pub-id pub-id-type="pmid">22406434</pub-id></mixed-citation></ref><ref id="jah32448-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jah32448-cit-0026">
<string-name>
<surname>Kumar</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Branch</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Pattillo</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Hood</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Thoma</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Simpson</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Illum</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Arora</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Chidlow</surname>
<given-names>JH</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Langston</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Teng</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Lefer</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Kevil</surname>
<given-names>CG</given-names>
</string-name>. <article-title>Chronic sodium nitrite therapy augments ischemia&#x02010;induced angiogenesis and arteriogenesis</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2008</year>;<volume>105</volume>:<fpage>7540</fpage>&#x02013;<lpage>7545</lpage>.<pub-id pub-id-type="pmid">18508974</pub-id></mixed-citation></ref><ref id="jah32448-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jah32448-cit-0027">
<string-name>
<surname>Noman</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ang</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Ogston</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lang</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Struthers</surname>
<given-names>AD</given-names>
</string-name>. <article-title>Effect of high&#x02010;dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial</article-title>. <source>Lancet</source>. <year>2010</year>;<volume>375</volume>:<fpage>2161</fpage>&#x02013;<lpage>2167</lpage>.<pub-id pub-id-type="pmid">20542554</pub-id></mixed-citation></ref><ref id="jah32448-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jah32448-cit-0028">
<string-name>
<surname>Schwarz</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Parasuraman</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Bruce</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shepstone</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Feelisch</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Minnion</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ahmad</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Horowitz</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Dawson</surname>
<given-names>DK</given-names>
</string-name>, <string-name>
<surname>Frenneaux</surname>
<given-names>MP</given-names>
</string-name>. <article-title>A randomized double&#x02010;blind placebo&#x02010;controlled crossover trial of sodium nitrate in patients with stable angina INAS</article-title>. <source>Future Cardiol</source>. <year>2016</year>;<volume>12</volume>:<fpage>617</fpage>&#x02013;<lpage>626</lpage>.<pub-id pub-id-type="pmid">27730819</pub-id></mixed-citation></ref><ref id="jah32448-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jah32448-cit-0029">
<string-name>
<surname>Bondonno</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Croft</surname>
<given-names>KD</given-names>
</string-name>, <string-name>
<surname>Considine</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Puddey</surname>
<given-names>IB</given-names>
</string-name>, <string-name>
<surname>Woodman</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Hodgson</surname>
<given-names>JM</given-names>
</string-name>. <article-title>Antibacterial mouthwash blunts oral nitrate reduction and increases blood pressure in treated hypertensive men and women</article-title>. <source>Am J Hypertens</source>. <year>2015</year>;<volume>28</volume>:<fpage>572</fpage>&#x02013;<lpage>575</lpage>.<pub-id pub-id-type="pmid">25359409</pub-id></mixed-citation></ref><ref id="jah32448-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jah32448-cit-0030">
<string-name>
<surname>Ghosh</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Kapil</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Fuentes&#x02010;Calvo</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Bubb</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Pearl</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Milsom</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Khambata</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Maleki&#x02010;Toyserkani</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yousuf</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Benjamin</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Webb</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Caulfield</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Hobbs</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Ahluwalia</surname>
<given-names>A</given-names>
</string-name>. <article-title>Enhanced vasodilator activity of nitrite in hypertension: critical role for erythrocytic xanthine oxidoreductase and translational potential</article-title>. <source>Hypertension</source>. <year>2013</year>;<volume>61</volume>:<fpage>1091</fpage>&#x02013;<lpage>1102</lpage>.<pub-id pub-id-type="pmid">23589565</pub-id></mixed-citation></ref><ref id="jah32448-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jah32448-cit-0031">
<string-name>
<surname>Chaitman</surname>
<given-names>BR</given-names>
</string-name>, <string-name>
<surname>Skettino</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Parker</surname>
<given-names>JO</given-names>
</string-name>, <string-name>
<surname>Hanley</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Meluzin</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kuch</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Pepine</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Nelson</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Hebert</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Wolff</surname>
<given-names>AA</given-names>
</string-name>. <article-title>Anti&#x02010;ischemic effects and long&#x02010;term survival during ranolazine monotherapy in patients with chronic severe angina</article-title>. <source>J Am Coll Cardiol</source>. <year>2004</year>;<volume>43</volume>:<fpage>1375</fpage>&#x02013;<lpage>1382</lpage>.<pub-id pub-id-type="pmid">15093870</pub-id></mixed-citation></ref><ref id="jah32448-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jah32448-cit-0032">
<string-name>
<surname>Schnaack</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Siegmund</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Spes</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Tammen</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Theisen</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Angermann</surname>
<given-names>CE</given-names>
</string-name>. <article-title>Transpulmonary contrast echocardiography: effects on delineation of endocardial border, assessment of wall motion and interobserver variability in stress echocardiograms of limited image quality</article-title>. <source>Coron Artery Dis</source>. <year>2000</year>;<volume>11</volume>:<fpage>549</fpage>&#x02013;<lpage>554</lpage>.<pub-id pub-id-type="pmid">11023243</pub-id></mixed-citation></ref><ref id="jah32448-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jah32448-cit-0033">
<string-name>
<surname>Ingram</surname>
<given-names>TE</given-names>
</string-name>, <string-name>
<surname>Fraser</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Bleasdale</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Ellins</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Margulescu</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Halcox</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>James</surname>
<given-names>PE</given-names>
</string-name>. <article-title>Low&#x02010;dose sodium nitrite attenuates myocardial ischemia and vascular ischemia&#x02010;reperfusion injury in human models</article-title>. <source>J Am Coll Cardiol</source>. <year>2013</year>;<volume>61</volume>:<fpage>2534</fpage>&#x02013;<lpage>2541</lpage>.<pub-id pub-id-type="pmid">23623914</pub-id></mixed-citation></ref><ref id="jah32448-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jah32448-cit-0034">
<string-name>
<surname>Siddiqi</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Bruce</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Neil</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Jagpal</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Maclennon</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Cotton</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Papadopoulo</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Bunce</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Lim</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Schwarz</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hildick&#x02010;Smith</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Horowitz</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Madhani</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Boon</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kaski</surname>
<given-names>J&#x02010;</given-names>
</string-name>, <string-name>
<surname>Dawson</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Frenneaux</surname>
<given-names>MP</given-names>
</string-name>. <article-title>Protocol: does sodium nitrite administration reduce ischaemia&#x02010;reperfusion injury in patients presenting with acute ST segment elevation myocardial infarction? Nitrites In Acute Myocardial Infarction (NIAMI)</article-title>. <source>J Transl Med</source>. <year>2013</year>;<volume>11</volume>:<fpage>116</fpage>.<pub-id pub-id-type="pmid">23648219</pub-id></mixed-citation></ref><ref id="jah32448-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jah32448-cit-0035">
<string-name>
<surname>Spertus</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Winder</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Dewhurst</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Deyo</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Prodzinski</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>McDonell</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fihn</surname>
<given-names>SD</given-names>
</string-name>. <article-title>Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease</article-title>. <source>J Am Coll Cardiol</source>. <year>1995</year>;<volume>25</volume>:<fpage>333</fpage>&#x02013;<lpage>341</lpage>.<pub-id pub-id-type="pmid">7829785</pub-id></mixed-citation></ref><ref id="jah32448-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="jah32448-cit-0036">
<string-name>
<surname>Dunselman</surname>
<given-names>PHJM</given-names>
</string-name>, <string-name>
<surname>Van Kempen</surname>
<given-names>LHJ</given-names>
</string-name>, <string-name>
<surname>Bouwens</surname>
<given-names>LHM</given-names>
</string-name>, <string-name>
<surname>Holwerda</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Herweijer</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Bernink</surname>
<given-names>PJLM</given-names>
</string-name>. <article-title>Value of the addition of amlodipine to atenolol in patients with angina pectoris despite adequate beta blockade</article-title>. <source>Am J Cardiol</source>. <year>1998</year>;<volume>81</volume>:<fpage>128</fpage>&#x02013;<lpage>132</lpage>.<pub-id pub-id-type="pmid">9591892</pub-id></mixed-citation></ref><ref id="jah32448-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="jah32448-cit-0037">
<string-name>
<surname>Knight</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Fox</surname>
<given-names>KM</given-names>
</string-name>. <article-title>Amlodipine versus diltiazem as additional antianginal treatment to atenolol</article-title>. <source>Am J Cardiol</source>. <year>1998</year>;<volume>81</volume>:<fpage>133</fpage>&#x02013;<lpage>136</lpage>.<pub-id pub-id-type="pmid">9591893</pub-id></mixed-citation></ref><ref id="jah32448-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="jah32448-cit-0038">
<string-name>
<surname>Tardif</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Ponikowski</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kahan</surname>
<given-names>T</given-names>
</string-name>. <article-title>Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta&#x02010;blocker therapy: a 4&#x02010;month, randomized, placebo&#x02010;controlled trial</article-title>. <source>Eur Heart J</source>. <year>2009</year>;<volume>30</volume>:<fpage>540</fpage>&#x02013;<lpage>548</lpage>.<pub-id pub-id-type="pmid">19136486</pub-id></mixed-citation></ref><ref id="jah32448-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="jah32448-cit-0039">
<string-name>
<surname>Chaitman</surname>
<given-names>BR</given-names>
</string-name>, <string-name>
<surname>Pepine</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Parker</surname>
<given-names>JO</given-names>
</string-name>, <string-name>
<surname>Skopal</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Chumakova</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Kuch</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Skettino</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Wolff</surname>
<given-names>AA</given-names>
</string-name>. <article-title>Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial</article-title>. <source>JAMA</source>. <year>2004</year>;<volume>291</volume>:<fpage>309</fpage>&#x02013;<lpage>316</lpage>.<pub-id pub-id-type="pmid">14734593</pub-id></mixed-citation></ref><ref id="jah32448-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="jah32448-cit-0040">
<string-name>
<surname>Thadani</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Nash</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bittar</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Glasser</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Narayan</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Stein</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Larkin</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mazzu</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tota</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Pomerantz</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sundaresan</surname>
<given-names>P</given-names>
</string-name>. <article-title>The effect of vardenafil, a potent and highly selective phosphodiesterase&#x02010;5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease</article-title>. <source>J Am Coll Cardiol</source>. <year>2002</year>;<volume>40</volume>:<fpage>2006</fpage>&#x02013;<lpage>2012</lpage>.<pub-id pub-id-type="pmid">12475462</pub-id></mixed-citation></ref><ref id="jah32448-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="jah32448-cit-0041">
<string-name>
<surname>Halcox</surname>
<given-names>JPJ</given-names>
</string-name>, <string-name>
<surname>Nour</surname>
<given-names>KRA</given-names>
</string-name>, <string-name>
<surname>Zalos</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Mincemoyer</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Waclawiw</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Rivera</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Willie</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Ellahham</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Quyyumi</surname>
<given-names>AA</given-names>
</string-name>. <article-title>The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia</article-title>. <source>J Am Coll Cardiol</source>. <year>2002</year>;<volume>40</volume>:<fpage>1232</fpage>&#x02013;<lpage>1240</lpage>.<pub-id pub-id-type="pmid">12383570</pub-id></mixed-citation></ref><ref id="jah32448-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="jah32448-cit-0042">
<string-name>
<surname>Fox</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Thadani</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Ma</surname>
<given-names>PT</given-names>
</string-name>, <string-name>
<surname>Nash</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Keating</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Czorniak</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Gillies</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Keltai</surname>
<given-names>M</given-names>
</string-name>; <collab collab-type="authors">CAESAR I (Clinical American and European Studies of Angina and Revascularization) investigators</collab>
. <article-title>Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina</article-title>. <source>Eur Heart J</source>. <year>2003</year>;<volume>24</volume>:<fpage>2206</fpage>&#x02013;<lpage>2212</lpage>.<pub-id pub-id-type="pmid">14659772</pub-id></mixed-citation></ref><ref id="jah32448-bib-0043"><label>43</label><mixed-citation publication-type="book" id="jah32448-cit-0043">
<string-name>
<surname>Senn</surname>
<given-names>S</given-names>
</string-name>. <source>Cross&#x02010;Over Trials in Clinical Research</source>, <edition>2nd ed</edition>
<publisher-loc>Chichester</publisher-loc>: <publisher-name>John Wiley &#x00026; Sons</publisher-name>; <year>1993</year>.</mixed-citation></ref><ref id="jah32448-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="jah32448-cit-0044">
<string-name>
<surname>Campeau</surname>
<given-names>L</given-names>
</string-name>. <article-title>Letter: grading of angina pectoris</article-title>. <source>Circulation</source>. <year>1976</year>;<volume>54</volume>:<fpage>522</fpage>&#x02013;<lpage>523</lpage>.</mixed-citation></ref><ref id="jah32448-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="jah32448-cit-0045">
<string-name>
<surname>Lai</surname>
<given-names>YC</given-names>
</string-name>, <string-name>
<surname>Tabima</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Dube</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Hughan</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Vanderpool</surname>
<given-names>RR</given-names>
</string-name>, <string-name>
<surname>Goncharov</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>St Croix</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Garcia&#x02010;Ocana</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Goncharova</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Tofovic</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Mora</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Gladwin</surname>
<given-names>MT</given-names>
</string-name>. <article-title>SIRT3&#x02010;AMP&#x02010;activated protein kinase activation by nitrite and metformin improves hyperglycemia and normalizes pulmonary hypertension associated with heart failure with preserved ejection fraction</article-title>. <source>Circulation</source>. <year>2016</year>;<volume>133</volume>:<fpage>717</fpage>&#x02013;<lpage>731</lpage>.<pub-id pub-id-type="pmid">26813102</pub-id></mixed-citation></ref><ref id="jah32448-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="jah32448-cit-0046">
<string-name>
<surname>Coggan</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Leibowitz</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Anderson Spearie</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kadkhodayan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Ramamurthy</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mahmood</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Waller</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Farmer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Peterson</surname>
<given-names>LR</given-names>
</string-name>. <article-title>Acute dietary nitrate intake improves muscle contractile function in patients with heart failure: a double&#x02010;blind, placebo&#x02010;controlled, randomized trial</article-title>. <source>Circ Heart Fail</source>. <year>2015</year>;<volume>8</volume>:<fpage>914</fpage>&#x02013;<lpage>920</lpage>.<pub-id pub-id-type="pmid">26179185</pub-id></mixed-citation></ref><ref id="jah32448-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="jah32448-cit-0047">
<string-name>
<surname>Zamani</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Rawat</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Shiva&#x02010;Kumar</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Geraci</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bhuva</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Konda</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Doulias</surname>
<given-names>PT</given-names>
</string-name>, <string-name>
<surname>Ischiropoulos</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Townsend</surname>
<given-names>RR</given-names>
</string-name>, <string-name>
<surname>Margulies</surname>
<given-names>KB</given-names>
</string-name>, <string-name>
<surname>Cappola</surname>
<given-names>TP</given-names>
</string-name>, <string-name>
<surname>Poole</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Chirinos</surname>
<given-names>JA</given-names>
</string-name>. <article-title>Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction</article-title>. <source>Circulation</source>. <year>2015</year>;<volume>131</volume>:<fpage>371</fpage>&#x02013;<lpage>380</lpage>; discussion 380.<pub-id pub-id-type="pmid">25533966</pub-id></mixed-citation></ref><ref id="jah32448-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="jah32448-cit-0048">
<string-name>
<surname>Hord</surname>
<given-names>NG</given-names>
</string-name>, <string-name>
<surname>Tang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Bryan</surname>
<given-names>NS</given-names>
</string-name>. <article-title>Food sources of nitrates and nitrites: the physiologic context for potential health benefits</article-title>. <source>Am J Clin Nutr</source>. <year>2009</year>;<volume>90</volume>:<fpage>1</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">19439460</pub-id></mixed-citation></ref><ref id="jah32448-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="jah32448-cit-0049">
<string-name>
<surname>Butler</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Feelisch</surname>
<given-names>M</given-names>
</string-name>. <article-title>Therapeutic uses of inorganic nitrite and nitrate: from the past to the future</article-title>. <source>Circulation</source>. <year>2008</year>;<volume>117</volume>:<fpage>2151</fpage>&#x02013;<lpage>2159</lpage>.<pub-id pub-id-type="pmid">18427145</pub-id></mixed-citation></ref><ref id="jah32448-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="jah32448-cit-0050">
<string-name>
<surname>Gilchrist</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Winyard</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Aizawa</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Anning</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Shore</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Benjamin</surname>
<given-names>N</given-names>
</string-name>. <article-title>Effect of dietary nitrate on blood pressure, endothelial function, and insulin sensitivity in type 2 diabetes</article-title>. <source>Free Radic Biol Med</source>. <year>2013</year>;<volume>60</volume>:<fpage>89</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">23395779</pub-id></mixed-citation></ref><ref id="jah32448-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="jah32448-cit-0051">
<string-name>
<surname>Lara</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ogbonmwan</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Oggioni</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Qadir</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Ashor</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Brandt</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Mathers</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Siervo</surname>
<given-names>M</given-names>
</string-name>. <article-title>Effects of handgrip exercise or inorganic nitrate supplementation on 24&#x02010;h ambulatory blood pressure and peripheral arterial function in overweight and obese middle age and older adults: a pilot RCT</article-title>. <source>Maturitas</source>. <year>2015</year>;<volume>82</volume>:<fpage>228</fpage>&#x02013;<lpage>235</lpage>.<pub-id pub-id-type="pmid">26316026</pub-id></mixed-citation></ref><ref id="jah32448-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="jah32448-cit-0052">
<string-name>
<surname>Pechanova</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Varga</surname>
<given-names>ZV</given-names>
</string-name>, <string-name>
<surname>Cebova</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Giricz</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Pacher</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Ferdinandy</surname>
<given-names>P</given-names>
</string-name>. <article-title>Cardiac NO signalling in the metabolic syndrome</article-title>. <source>Br J Pharmacol</source>. <year>2015</year>;<volume>172</volume>:<fpage>1415</fpage>&#x02013;<lpage>1433</lpage>.<pub-id pub-id-type="pmid">25297560</pub-id></mixed-citation></ref><ref id="jah32448-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="jah32448-cit-0053">
<string-name>
<surname>Pinheiro</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Montenegro</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Amaral</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Ferreira</surname>
<given-names>GC</given-names>
</string-name>, <string-name>
<surname>Oliveira</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Tanus&#x02010;Santos</surname>
<given-names>JE</given-names>
</string-name>. <article-title>Increase in gastric pH reduces hypotensive effect of oral sodium nitrite in rats</article-title>. <source>Free Radic Biol Med</source>. <year>2012</year>;<volume>53</volume>:<fpage>701</fpage>&#x02013;<lpage>709</lpage>.<pub-id pub-id-type="pmid">22721923</pub-id></mixed-citation></ref><ref id="jah32448-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="jah32448-cit-0054">
<string-name>
<surname>Montenegro</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Lundberg</surname>
<given-names>JO</given-names>
</string-name>. <article-title>Letter by Montenegro and Lundberg regarding article, &#x0201c;Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine&#x0201d;</article-title>. <source>Circulation</source>. <year>2014</year>;<volume>129</volume>:<fpage>e426</fpage>.<pub-id pub-id-type="pmid">24687652</pub-id></mixed-citation></ref><ref id="jah32448-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="jah32448-cit-0055">
<string-name>
<surname>Pinheiro</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Amaral</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Tanus&#x02010;Santos</surname>
<given-names>JE</given-names>
</string-name>. <article-title>Letter by Pinheiro et&#x000a0;al. regarding article, &#x0201c;unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine&#x0201d;</article-title>. <source>Circulation</source>. <year>2014</year>;<volume>129</volume>:<fpage>e427</fpage>.<pub-id pub-id-type="pmid">24687653</pub-id></mixed-citation></ref><ref id="jah32448-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="jah32448-cit-0056">
<string-name>
<surname>Montenegro</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Sundqvist</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Larsen</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>Zhuge</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Carlstrom</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Weitzberg</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Lundberg</surname>
<given-names>JO</given-names>
</string-name>. <article-title>Blood pressure&#x02010;lowering effect of orally ingested nitrite is abolished by a proton pump inhibitor</article-title>. <source>Hypertension</source>. <year>2017</year>;<volume>69</volume>:<fpage>23</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">27802417</pub-id></mixed-citation></ref><ref id="jah32448-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="jah32448-cit-0057">
<string-name>
<surname>Machha</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Schechter</surname>
<given-names>AN</given-names>
</string-name>. <article-title>Inorganic nitrate: a major player in the cardiovascular health benefits of vegetables?</article-title>
<source>Nutr Rev</source>. <year>2012</year>;<volume>70</volume>:<fpage>367</fpage>&#x02013;<lpage>372</lpage>.<pub-id pub-id-type="pmid">22646129</pub-id></mixed-citation></ref></ref-list></back></article>